AI in Healthcare Diagnostics—AI systems diagnosing diseases from medical data.

      By /

      AI is revolutionizing healthcare diagnostics by analyzing vast amounts of medical data to assist clinicians in identifying diseases more accurately and efficiently. This application of AI is highly sensitive, making AI Governance & Trust (AI TRiSM) absolutely critical for patient safety, equitable care, and public trust.

      AI in Healthcare Diagnostics: How It Works

      AI systems diagnose diseases from medical data by leveraging various subfields like machine learning (ML), deep learning, natural language processing (NLP), and computer vision. They analyze diverse data types, including

      1. Medical Imaging:
        • How it works: Deep learning models, particularly Convolutional Neural Networks (CNNs), are trained on vast datasets of medical images (X-rays, MRIs, CT scans, mammograms, ultrasounds, and pathology slides). They learn to detect subtle patterns, anomalies, and lesions that might be missed by the human eye or are too small to be easily identified.
        • Examples: detecting lung nodules in X-rays, identifying cancerous cells in pathology slides, spotting fractures in bone scans, early detection of breast cancer in mammograms, and identifying signs of stroke or hemorrhage in brain scans.
        • Impact: Speeds up diagnosis, reduces diagnostic errors, helps triage urgent cases, and can even identify diseases before symptoms appear.
      2. Electronic Health Records (EHRs) and Clinical Notes:
        • How it works: NLP and ML algorithms process unstructured text data from clinical notes, discharge summaries, and physician reports, alongside structured data from EHRs (patient history, lab results, medications, vital signs, and genetic information). They extract key insights, identify correlations, and recognize patterns indicative of disease.
        • Examples: predicting sepsis risk early from vital signs and lab results, identifying patients at risk for chronic conditions like diabetes or heart failure, assisting in rare disease diagnosis by linking seemingly unrelated symptoms, and summarizing patient medical histories for faster review.
        • Impact: Enhances clinical decision support, reduces administrative burden, and enables real-time abnormality detection.
      3. Genomic and Multi-omics Data:
        • How it works: AI algorithms analyze complex genomic sequences, gene expression profiles, and other “omics” data (proteomics, metabolomics) to identify genetic mutations, biomarkers, and pathways associated with specific diseases.
        • Examples: diagnosing rare genetic disorders, identifying genetic predispositions to cancers (e.g., BRCA mutations), predicting individual drug responses (pharmacogenomics), and aiding in precision medicine by tailoring treatments based on a patient’s unique genetic makeup.
        • Impact: Revolutionizes personalized medicine, accelerates understanding of disease mechanisms, and enables earlier, more targeted interventions.
      4. Laboratory Test Results & Biomarkers:
        • How it works: AI identifies abnormal patterns or correlations in blood tests, urine analyses, and other lab results that might indicate disease or an elevated risk.
        • Examples: Detecting early signs of kidney disease, liver dysfunction, or certain infections from blood chemistry panels. Identifying specific biomarkers linked to inflammatory conditions or early-stage cancers.
        • Impact: Improves the accuracy and speed of interpreting complex lab data.

      The Indispensable Role of AI Governance & Trust (AI TRiSM)

      Given the life-altering nature of medical diagnoses, AI TRiSM is not merely beneficial but absolutely essential in healthcare diagnostics. It directly addresses the critical concerns of fairness, transparency, and safety.

      Ensuring Fairness in Healthcare Diagnostics:

      • The Risk of Bias:
        • Data Bias: AI models trained on unrepresentative patient data (e.g., predominantly male, Caucasian, or from a specific socioeconomic group) may perform poorly or inaccurately on patients from underrepresented groups. This can lead to misdiagnosis, delayed diagnosis, or incorrect treatment recommendations for certain populations. For example, AI models for dermatological conditions have shown bias against darker skin tones due to insufficient diverse training images.
        • Algorithm Bias: Even with diverse data, the algorithm itself might inadvertently learn and amplify subtle biases in the data, leading to disparate outcomes.
      • How AI TRiSM Addresses Fairness:
        • Diverse Data Curation: Strict governance over data sourcing ensures that training datasets are representative of all relevant patient demographics, including age, gender, ethnicity, socioeconomic status, and medical conditions.
        • Bias Detection & Mitigation: Implementing rigorous testing for algorithmic bias using fairness metrics (e.g., ensuring similar sensitivity and specificity across different demographic groups). If bias is detected, techniques like data re-sampling, re-weighting, or algorithmic adjustments are applied to mitigate it.
        • Subgroup Analysis: Performance evaluations disaggregate results by patient subgroups to confirm equitable accuracy and error rates.
        • Ethical Review Boards: AI ethics committees review diagnostic AI systems for potential societal impact and ethical implications before deployment.

      Ensuring Transparency in Healthcare Diagnostics:

      • The “Black Box” Problem: Clinicians and patients need to understand why an AI system arrived at a particular diagnosis. A “black box” AI that simply states “Disease X detected” without explanation is problematic for clinical trust, legal accountability, and informed consent.
        • Accountability: If an AI makes an incorrect diagnosis, who is responsible? The developer? The prescribing physician? Transparency is crucial for assigning liability.
        • Clinician Trust & Adoption: Doctors are unlikely to trust and adopt tools they don’t understand, especially when patient lives are at stake.
        • Patient Autonomy: Patients have a right to understand their diagnosis and treatment plan, which is complicated if AI decisions are opaque.
      • How AI TRiSM Addresses Transparency:
        • Explainable AI (XAI): This is paramount in healthcare. Diagnostic AI systems are increasingly required to:
          • Highlight Evidence: For imaging AI, it should delineate the exact regions in the scan that led to the diagnosis (e.g., heatmaps, bounding boxes).
          • Cite Contributing Factors: For EHR analysis, it should list the specific symptoms, lab results, or historical data points that influenced the diagnosis.
          • Provide Confidence Scores: Indicate the AI’s level of certainty in its diagnosis.
        • Comprehensive Documentation: Detailed “model cards” or “datasheets for datasets” are created, outlining the AI’s intended use, development process, training data characteristics, performance metrics (including fairness), known limitations, and potential biases.
        • Human-in-the-Loop: AI is used as a diagnostic aid or decision support tool, not a replacement for human clinicians. The final diagnosis and treatment decision always remain with the physician, who uses the AI’s insights as one piece of evidence. This ensures human oversight and accountability.
        • Clear Communication with Patients: Healthcare providers are trained to explain AI’s role in the diagnostic process to patients in an understandable manner, ensuring informed consent.

      Other Critical AI TRiSM Pillars in Healthcare Diagnostics:

      • Privacy: Utmost importance in healthcare. AI TRiSM mandates robust data anonymization, encryption, access controls, and adherence to regulations like HIPAA and GDPR to protect sensitive patient health information. Privacy-preserving AI techniques like federated learning (training models on decentralized hospital data without data leaving the hospital) are gaining traction.
      • Security: Protecting diagnostic AI systems from cyberattacks, data poisoning (maliciously altering training data to cause misdiagnosis), or adversarial attacks (subtle input manipulations to trick the AI).
      • ModelOps: Continuous monitoring of diagnostic AI systems in real-time to detect performance degradation, drift in accuracy over time (e.g., due to evolving disease patterns), or new biases. This ensures that a diagnostic AI remains effective and safe throughout its operational life.
      • Regulatory Compliance: Navigating complex regulatory landscapes (e.g., FDA approval for medical devices, the EU AI Act’s “high-risk” designation for diagnostic AI) is a major driver for implementing robust AI TRiSM.

      In conclusion, AI in healthcare diagnostics holds immense promise, but its responsible and effective implementation hinges entirely on the integration of AI governance and trust. By meticulously focusing on fairness, transparency, and security, healthcare providers can harness AI’s power to deliver more accurate, efficient, and equitable diagnoses, ultimately leading to better patient outcomes and a more trustworthy healthcare system.

      What is AI in healthcare diagnostics—AI systems diagnosing diseases from medical data?

      Types of Medical Data Used by AI:

      AI systems for diagnostics are trained on and analyze a diverse range of medical data, including:

      • Medical Imaging: This is one of the most mature and impactful areas. It includes:
        • Radiology images: X-rays, CT scans, MRIs, PET scans.
        • Pathology slides: Digitized tissue samples.
        • Ophthalmology images: Retinal scans.
        • Dermatology images: Photographs of skin lesions.
        • Ultrasound images.
      • Electronic Health Records (EHRs): Structured data like patient demographics, medical history, diagnoses codes, medication lists, lab results, and vital signs.
      • Clinical Notes & Unstructured Text: Physician notes, discharge summaries, surgical reports, etc., which are often in free-text format and require Natural Language Processing (NLP) for extraction and analysis.
      • Genomic and Multi-omics Data: DNA sequences, gene expression profiles (RNA-seq), proteomics, metabolomics, and other high-dimensional biological data.
      • Laboratory Test Results & Biomarkers: Blood tests, urine tests, biopsy results, and specific molecular markers indicative of disease.
      • Physiological Signals: ECG (electrocardiogram), EEG (electroencephalogram), EMG (electromyogram), continuous glucose monitoring, heart rate, blood pressure, etc.
      • Wearable Device Data: Data from smartwatches and other wearable sensors that monitor activity, sleep, heart rate, and other health metrics.
      • Vocal Biomarkers: Analysis of speech patterns, tone, and pitch for early detection of mental health conditions or neurological disorders.

      2. How AI Diagnoses from This Data:

      AI systems, predominantly using machine learning (ML) and deep learning (DL) algorithms, employ various techniques:

      • Pattern Recognition: AI excels at identifying subtle patterns and correlations within complex datasets that might be too intricate or voluminous for humans to discern.
        • Example: In medical imaging, a Deep Learning model (like a Convolutional Neural Network – CNN) can learn to detect minute features on an X-ray that indicate a lung nodule, even if it’s very small or obscured.
      • Classification: Categorizing input data into predefined classes (e.g., “malignant” vs. “benign,” “diseased” vs. “healthy”).
        • Example: An AI trained on pathology slides can classify cells as cancerous or non-cancerous.
      • Segmentation: Identifying and outlining specific structures or anomalies within an image.
        • Example: Segmenting a tumor from surrounding healthy brain tissue on an MRI.
      • Predictive Analytics: Forecasting the likelihood of a disease, its progression, or a patient’s response to treatment based on historical data.
        • Example: Predicting the risk of sepsis in ICU patients based on real-time vital signs and lab results.
      • Natural Language Processing (NLP): Understanding and extracting relevant information from unstructured clinical notes and converting it into structured data for analysis.
        • Example: Sifting through thousands of patient notes to identify specific symptoms or comorbidities that suggest a rare disease.
      • Anomaly Detection: Identifying data points that deviate significantly from expected patterns, often indicating a potential issue.
        • Example: Flagging unusual changes in a patient’s continuous glucose monitoring data that could indicate impending hypoglycemia or hyperglycemia.

      3. Key Applications and Examples:

      • Radiology:
        • Early Lung Cancer Detection: AI can analyze chest CT scans to identify small lung nodules that might be missed by human radiologists.
        • Breast Cancer Screening: AI assists in interpreting mammograms, reducing false positives and helping detect subtle signs of cancer.
        • Stroke Detection: Rapidly analyzing brain CT scans to identify signs of stroke (ischemic or hemorrhagic), enabling quicker intervention.
        • Fracture Detection: Identifying hidden or subtle bone fractures in X-rays.
      • Pathology:
        • Cancer Diagnosis: AI analyzes digitized biopsy slides to identify cancerous cells, classify tumor types, and assess tumor aggressiveness, significantly speeding up the process.
      • Ophthalmology:
        • Diabetic Retinopathy: Detecting early signs of diabetic retinopathy from retinal scans, preventing vision loss.
        • Glaucoma Detection: Analyzing optic nerve images to identify signs of glaucoma.
      • Cardiology:
        • Heart Disease Detection: Analyzing ECGs, echocardiograms, and cardiac MRI/CT scans to detect heart conditions like arrhythmias or coronary artery disease.
      • Dermatology:
        • Skin Cancer Screening: AI analyzes images of moles and skin lesions to assess the risk of melanoma.
      • Rare Disease Diagnosis: Integrating diverse patient data (symptoms, genetic tests, family history) to identify patterns indicative of rare or complex diseases that are difficult for clinicians to diagnose.
      • Sepsis Prediction: Monitoring vital signs and lab results in real-time to predict the onset of sepsis, a life-threatening condition.
      • Genetic Disease Identification: Analyzing genomic sequences to identify mutations or patterns associated with inherited diseases or predispositions to conditions like certain cancers (e.g., BRCA mutations).

      4. Impact and Benefits:

      • Improved Accuracy: AI can often detect subtle patterns and anomalies that human clinicians might overlook, leading to more accurate diagnoses.
      • Increased Speed: AI can process vast amounts of data much faster than humans, accelerating diagnosis, especially in time-sensitive conditions.
      • Enhanced Efficiency: Automating routine tasks like initial screening or image analysis frees up clinicians’ time to focus on complex cases and patient interaction.
      • Early Detection: AI’s ability to spot minute changes can enable earlier disease detection, which is crucial for conditions like cancer where early intervention dramatically improves outcomes.
      • Reduced Human Error: AI provides a consistent and objective analysis, reducing inter-observer variability among clinicians.
      • Accessibility: AI-powered tools can potentially extend diagnostic capabilities to underserved areas, or assist less experienced clinicians.
      • Personalized Medicine: By integrating various data types, AI can help tailor diagnostic approaches and treatment plans to an individual patient’s unique biological profile.

      In essence, AI in healthcare diagnostics acts as a powerful assistant to medical professionals, augmenting their capabilities and transforming the diagnostic landscape to provide more precise, timely, and effective patient care. However, because of the high stakes involved, the ethical, fair, and transparent deployment of these AI systems, guided by AI TRiSM, is paramount.

      Who is Required AI in Healthcare Diagnostics—AI systems diagnosing diseases from medical data?

      Courtesy: NBC News

      AI System Developers and Vendors:

      This includes technology companies, startups, and research institutions that design, train, and build AI models for diagnostic purposes.

      • Responsibility: They are primarily responsible for the technical integrity, accuracy, fairness, and security of the AI models.
        • Data Sourcing & Curation: Ensuring the use of diverse, representative, high-quality, and ethically sourced medical data for training. They must actively identify and mitigate biases in the datasets.
        • Algorithm Design: Developing algorithms that are robust, accurate across different patient populations, and ideally, offer some level of explainability.
        • Validation & Testing: Rigorously testing AI models against large, independent datasets to ensure accuracy, sensitivity, specificity, and most importantly, fairness across various demographic groups.
        • Explainable AI (XAI): Building in mechanisms for explanations and interpretability, allowing clinicians to understand why a diagnosis is suggested.
        • Security: Implementing strong cybersecurity measures to protect the AI model itself, its data, and the pipelines from malicious attacks (e.g., data poisoning, adversarial attacks) or unauthorized access.
        • Privacy: Adhering to strict data privacy regulations (e.g., HIPAA in the US, GDPR in Europe, India’s DPDPA) throughout the entire development and deployment lifecycle.
        • Documentation: Providing comprehensive documentation on the AI model’s intended use, limitations, known biases, performance metrics, and validation procedures.

      2. Healthcare Providers (Hospitals, Clinics, Physicians, Radiologists, Pathologists):

      These are the primary users and beneficiaries of diagnostic AI systems.

      • Responsibility: They are responsible for the clinical integration, responsible use, and ethical application of AI in patient care.
        • Clinical Validation: Conducting their own internal validation or participating in clinical trials to assess the AI’s performance in their specific clinical context and patient population.
        • Human Oversight: Ensuring that AI acts as a decision support tool rather than an autonomous decision-maker. The final diagnosis and treatment decision must always remain with the qualified human clinician.
        • Training & Education: Training clinicians on how to effectively use AI tools, interpret their outputs, understand their limitations, and identify potential biases.
        • Patient Communication: Clearly explaining to patients when AI is being used in their diagnosis, what its role is, and its potential benefits and limitations.
        • Monitoring & Feedback: Continuously monitoring the performance of deployed AI systems in their practice and providing feedback to developers for improvement.
        • Ethical Deployment: Ensuring that the use of AI aligns with ethical guidelines and avoids exacerbating health disparities.

      3. Regulatory Bodies and Government Agencies:

      These entities establish the rules, guidelines, and frameworks for the safe and ethical use of AI in healthcare.

      • Responsibility: They ensure patient safety, protect public health, and promote responsible innovation.
        • Certification/Approval: Agencies like the FDA (U.S.) and EMA (Europe) classify AI diagnostic tools as medical devices and subject them to rigorous review processes for safety, efficacy, and quality. The EU AI Act, for example, categorizes AI in diagnostics as “high-risk.”
        • Guidelines & Standards: Developing and updating guidelines for AI development, testing, deployment, and post-market surveillance (e.g., NIST AI Risk Management Framework, WHO guidelines on AI in health).
        • Addressing Bias & Fairness: Mandating requirements for bias testing, fairness metrics, and transparency from AI developers.
        • Data Governance & Privacy: Enforcing data protection laws and ensuring responsible handling of sensitive patient data.
        • Accountability & Liability: Establishing frameworks for accountability when AI systems cause harm or error.
        • Promoting Innovation: Balancing regulation with the need to foster innovation in AI for healthcare.

      4. Patients and Patient Advocacy Groups:

      As the ultimate beneficiaries and impacted individuals, patients play a crucial role in demanding trustworthy AI.

      • Responsibility: While not directly “required” to manage AI, their needs and concerns drive the necessity for AI TRiSM.
        • Informed Consent: Patients have the right to be informed about the use of AI in their diagnosis and to understand the implications.
        • Trust & Confidence: Their acceptance and trust in AI systems are vital for widespread adoption. If AI is perceived as biased or opaque, patient distrust will hinder its progress.
        • Feedback: Providing feedback on their experiences with AI-augmented diagnostics, including any perceived biases or errors.
        • Advocacy: Patient advocacy groups play a role in shaping policies and demanding ethical AI development and deployment.

      5. Researchers and Academia:

      These groups contribute to the foundational knowledge, development of best practices, and independent evaluation of AI in healthcare.

      • Responsibility: Advancing the field, identifying new risks, and developing solutions.
        • Ethical AI Research: Conducting research into AI bias, fairness metrics, explainability techniques, and robust AI security.
        • Independent Validation: Performing independent studies to validate the performance and safety of AI diagnostic tools.
        • Developing Standards: Contributing to the development of industry-wide standards and best practices for AI in healthcare.

      In summary, the requirement for AI in Healthcare Diagnostics falls on a collaborative ecosystem. No single entity can ensure the trustworthiness of these powerful tools alone. It necessitates a shared commitment to ethical principles, rigorous validation, continuous monitoring, and transparent communication across all stakeholders.

      When is Required AI in Healthcare Diagnostics—AI systems diagnosing diseases from medical data?

      Immediately (Present Day and Growing Imperative):

      • For Enhanced Accuracy and Early Detection: In conditions where early diagnosis is critical for patient outcomes (e.g., many cancers, diabetic retinopathy, stroke), AI is becoming required to augment human capabilities. AI can detect subtle patterns that humans might miss, leading to earlier and more accurate diagnoses. For instance, in India, AI-powered screening tools are already proving valuable for early breast cancer and TB detection, and diabetic retinopathy, particularly in low-resource settings.
      • To Address Resource Shortages and Improve Accessibility: In countries like India, with a vast and diverse population and challenges in accessing specialized medical professionals, AI is increasingly required to bridge gaps in healthcare accessibility. AI-powered diagnostics can be deployed in remote areas, assisting primary healthcare workers and reducing the burden on overstretched urban hospitals.
      • To Process Voluminous and Complex Data: The sheer volume of medical data (images, EHRs, genomics) is overwhelming for human analysis alone. AI is required to efficiently process, interpret, and extract actionable insights from this data, especially in specialties like radiology and pathology.
      • For Consistency and Reduced Variability: Traditional diagnostic methods can be subjective. AI provides consistent, data-driven insights, reducing variability in outcomes among different medical professionals. This consistency is required for maintaining high standards of care.
      • In High-Volume Screening Programs: For large-scale public health screening initiatives (e.g., for tuberculosis, diabetic retinopathy), AI is required to automate initial screening, identify high-risk individuals, and triage cases efficiently, making these programs more cost-effective and scalable.

      2. Throughout the AI Development and Deployment Lifecycle (Ongoing Requirement):

      The “when” for the responsible deployment of AI in healthcare diagnostics means integrating AI Governance & Trust (AI TRiSM) at every stage:

      • During Development and Training: From the moment data is collected for training, AI TRiSM (especially fairness, privacy, and security measures) is required. Biases must be identified and mitigated before the model is deployed.
      • During Clinical Validation: Before any diagnostic AI tool is used on patients, rigorous clinical validation is required to prove its safety, efficacy, and generalizability across diverse populations. This involves prospective studies in real-world clinical settings.
      • Upon Regulatory Approval: As AI diagnostic tools are increasingly classified as medical devices (e.g., by the FDA in the US, under the EU AI Act in Europe), regulatory approval is required for their market entry. These approvals often necessitate extensive data on performance, safety, and sometimes, fairness and transparency. In India, the Medical Device Rules, 2017, and its 2020 amendment include software or accessories intended for medical use, implicitly covering many AI diagnostic tools.
      • Post-Deployment (Continuous Monitoring): Once deployed, AI diagnostic systems require continuous monitoring (ModelOps) to detect performance degradation (model drift), data drift, or emergent biases over time. Regular audits are required to ensure the AI continues to perform accurately, fairly, and securely.
      • With Evolving Medical Knowledge and Technology: As new medical knowledge emerges or AI technology itself advances (e.g., new foundation models), AI diagnostic systems require regular updates, retraining, and re-validation to remain current and effective.

      3. As Regulatory Frameworks Mature (Upcoming Formal Requirements):

      While AI is already in use, more formal and stringent requirements are emerging:

      • EU AI Act: This landmark regulation, entering into force on August 1, 2024 (with full applicability by August 2026 for “high-risk” systems like diagnostic AI), requires developers and deployers of such systems to adhere to strict rules concerning risk management, data quality, transparency, human oversight, robustness, and security.
      • Indian Regulatory Landscape: While India has a “pro-innovation” approach, discussions around specific regulations for “high-risk AI systems” (as mentioned in the Digital India Act blueprint) are ongoing. The ICMR’s “Ethical Guidelines for Application of Artificial Intelligence in Biomedical Research and Healthcare” already outlines ethical issues. As AI adoption scales, formal regulatory mandates for fairness, transparency, and accountability in diagnostic AI will become more explicit and required.
      • Industry Standards and Best Practices: Even in the absence of explicit government regulation, industry bodies and healthcare organizations are increasingly adopting their own internal standards and best practices for responsible AI, making robust AI TRiSM required for market competitiveness and reputation.

      In conclusion, AI in healthcare diagnostics is not just a future potential; it is already being adopted and is increasingly required to address pressing challenges in healthcare delivery. The “when” is multifaceted: it’s required now for its clinical benefits, continuously throughout its lifecycle for responsible deployment, and imminently as regulatory bodies worldwide establish clear frameworks for its safe, fair, and transparent use.

      Where is required AI in healthcare diagnostics—AI systems diagnosing diseases from medical data?

      Urban Hospitals and Large Diagnostic Chains:

      • Where: Major metropolitan hospitals, super-specialty hospitals, and large private diagnostic laboratories in cities like Mumbai, Delhi, Bengaluru, Chennai, Hyderabad, etc.
      • Why: These institutions handle a high volume of complex cases and extensive digital data (e.g., medical images, EHRs). AI is crucial for:
        • Speed and Efficiency: Rapidly analyzing large numbers of X-rays, CT scans, MRIs, and pathology slides, reducing turnaround times for diagnoses.
        • Complex Case Support: Assisting specialists (radiologists, pathologists, oncologists) in detecting subtle anomalies or confirming diagnoses in challenging cases.
        • Research & Development: These centers often have the infrastructure and expertise to collaborate with AI developers and integrate cutting-edge AI tools.
      • Examples in India:
        • Qure.ai (Mumbai): Provides AI-powered interpretation of radiology exams (X-rays, CTs) for faster diagnosis, used in various hospitals.
        • Aravind Eye Hospitals (Tamil Nadu): Collaborates with Google to use AI for detecting cataracts, glaucoma, and diabetic retinopathy from retinal images.
        • Narayana Health (Bengaluru): Collaborated with Microsoft to interpret echocardiograms using AI for early detection of cardiac abnormalities.
        • Apollo Hospitals (Pan-India): Launched the Apollo Clinical Intelligence Engine (CIE), an AI-driven clinical decision support tool for doctors.

      2. Rural and Semi-Urban Healthcare Settings:

      • Where: Primary Healthcare Centers (PHCs), eClinics, smaller hospitals, and mobile diagnostic units in remote and underserved areas.
      • Why: AI is becoming increasingly required to bridge the significant healthcare accessibility gap and address the shortage of specialists in these regions.
        • Democratizing Access: Enabling basic diagnostic capabilities where specialists are scarce or unavailable.
        • Early Screening: Facilitating mass screening programs for common diseases (e.g., TB, diabetic retinopathy, oral cancer) at the point of care.
        • Decision Support for General Practitioners: Empowering less-trained healthcare personnel with AI-driven insights to make more accurate initial diagnoses.
      • Examples in India:
        • Remidio’s AI-based Fundus on Phone: Allows general practitioners to screen for diabetic retinopathy without needing a retina specialist, particularly useful in rural settings.
        • Mobile Cancer Detection Hubs: Initiatives in Telangana and Uttar Pradesh leverage AI to improve early disease detection in underserved populations.
        • AI-driven Diagnostic Labs: Being established in regions like Himachal Pradesh to make advanced diagnostics more affordable and accessible.
        • CureBay’s eClinics: Utilize AI-driven tools for diagnostic accuracy and remote consultations in rural areas.

      3. Specialized Diagnostic Fields with High Data Volume:

      • Where: Dedicated labs and departments within hospitals or standalone centers focusing on:
        • Radiology: Due to the abundance of digital images.
        • Pathology: With the advent of digital pathology (scanning microscope slides).
        • Ophthalmology: Given the image-centric nature of eye diagnostics.
        • Genomics: For analyzing complex genetic sequences.
      • Why: AI’s ability to analyze large image datasets, complex genetic information, or intricate lab results makes it indispensable.
        • Precision: Identifying subtle features or complex patterns that are difficult for human eyes alone.
        • Efficiency: Automating tedious or repetitive tasks, such as initial screening of slides or scans.
      • Examples in India:
        • NIRAMAI (Bengaluru): Uses AI-powered thermal imaging (Thermalytix) for early, non-invasive breast cancer detection.
        • SigTuple (Bengaluru): Employs an AI platform (Manthana) for automated analysis of blood smears and digitizing blood, urine, and semen samples.
        • Bioheaven360 Genotec (Delhi): Introduced an AI-powered genomics diagnostics platform for early disease detection and personalized treatment plans, developed in collaboration with AIIMS.

      4. Public Health Programs and Government Initiatives:

      • Where: Government-backed health programs and large-scale public health surveillance systems.
      • Why: AI is required to enhance the reach, effectiveness, and efficiency of public health efforts.
        • Population Health Management: Identifying at-risk populations for specific diseases based on demographic, environmental, and historical data.
        • Disease Surveillance: Early detection of outbreaks and tracking disease spread.
        • Optimizing Resource Allocation: Using predictive analytics to anticipate healthcare needs and allocate resources effectively.
      • Examples in India:
        • Microsoft’s Project Netra/MINE: Collaboration with the Government of Telangana to use AI to reduce avoidable blindness in children.
        • Various government-backed initiatives: Like the IndiaAI Mission, which aims to leverage AI for public good, including healthcare.

      5. Research and Development Institutions:

      • Where: Academic medical centers, research laboratories, and pharmaceutical companies.
      • Why: AI is essential for accelerating discovery and understanding disease mechanisms.
        • Biomarker Discovery: Identifying new indicators of disease from complex data.
        • Drug Target Identification: Speeding up the drug discovery process by predicting promising compounds.
        • Understanding Disease Etiology: Gaining deeper insights into the causes and progression of diseases.

      In essence, AI in healthcare diagnostics is becoming a required tool wherever there’s a need to improve diagnostic accuracy, increase efficiency, expand access to care, or manage large, complex medical datasets. This spans from the most advanced urban hospitals to the most underserved rural clinics, demonstrating its versatility and growing indispensability.

      How is required AI in healthcare diagnostics—AI systems diagnosing diseases from medical data?

      By Enhancing Diagnostic Accuracy and Precision:

      • Pattern Recognition Beyond Human Capacity: AI, especially deep learning algorithms (like Convolutional Neural Networks for images), can analyze vast amounts of medical data (imaging, genomics, EHRs) and identify subtle patterns, correlations, and anomalies that are often invisible or too complex for the human eye or brain to consistently detect.
        • How it’s required: In fields like radiology and pathology, AI is required to spot early signs of disease (e.g., tiny lung nodules on a CT scan, microscopic cancerous cells on a biopsy slide, subtle changes in retinal images indicative of diabetic retinopathy) that might be missed by human observation, even by experienced specialists. This directly leads to earlier and more accurate diagnoses.
      • Reducing Human Error and Variability: Human interpretation of medical data can be subjective and prone to fatigue or cognitive biases. AI provides consistent, objective analysis.
        • How it’s required: AI is required to serve as a “second pair of eyes” or a “quality control check” for clinicians, reducing diagnostic errors and ensuring more consistent diagnoses across different practitioners and institutions. This is especially vital in high-stakes situations.
      • Integrating Multimodal Data for Holistic Views: AI can simultaneously analyze diverse data types (images, lab results, clinical notes, genetic information) to create a more comprehensive patient profile.
        • How it’s required: This capability is required for precision diagnostics, allowing AI to identify complex interactions between different patient factors that might indicate a rare disease or predict a patient’s response to a specific treatment, leading to personalized medicine.

      2. By Accelerating the Diagnostic Workflow and Increasing Efficiency:

      • Automating Routine and Repetitive Tasks: A significant portion of diagnostic work involves repetitive tasks like screening large numbers of images or organizing patient data.
        • How it’s required: AI automates these tasks, freeing up highly skilled healthcare professionals (radiologists, pathologists) to focus on more complex cases, patient consultations, and research. For example, AI can triage urgent scans, flagging critical cases for immediate human review, or filter out “normal” scans.
      • Reducing Turnaround Times: Faster analysis directly translates to quicker diagnoses.
        • How it’s required: In time-sensitive conditions like stroke, sepsis, or acute cardiac events, AI’s speed in analyzing scans or vital signs is crucial for rapid intervention, which can be life-saving. In India, where patient volumes are high, AI is required to speed up screening and diagnosis for prevalent diseases like TB.
      • Optimizing Resource Allocation: By streamlining diagnostic processes, AI can help healthcare systems manage higher patient volumes more efficiently.
        • How it’s required: This helps reduce patient wait times for diagnostic tests and results, improving patient experience and making healthcare more accessible and affordable, especially in regions with limited resources.

      3. By Expanding Access to Diagnostics:

      • Bridging the Specialist Gap: Many regions, particularly rural and semi-urban areas in India, suffer from a severe shortage of specialized medical professionals (radiologists, pathologists, oncologists).
        • How it’s required: AI-powered diagnostic tools can act as an extension of specialists, allowing general practitioners or community health workers to perform preliminary screenings and obtain AI-assisted diagnoses. This democratizes access to expert-level diagnostic capabilities where human specialists are scarce.
      • Enabling Point-of-Care Diagnostics: AI can be integrated into portable devices or smartphone applications.
        • How it’s required: This enables diagnostics to happen closer to the patient, even in remote locations, without the need for sophisticated lab equipment or immediate access to a specialist. For example, AI can analyze photos of skin lesions for cancer risk or process retinal images for diabetic retinopathy right in a primary care clinic.

      4. By Facilitating Early Disease Detection and Predictive Capabilities:

      • Proactive Health Monitoring: AI can analyze continuous data from wearables and other monitoring devices.
        • How it’s required: This allows for the early detection of deviations from normal health patterns, enabling proactive interventions before a disease fully manifests or becomes severe. For example, predicting the risk of cardiovascular events or diabetes progression.
      • Identifying At-Risk Individuals: AI can analyze large population health datasets to identify individuals at higher risk for certain conditions based on a combination of genetic, lifestyle, and environmental factors.
        • How it’s required: This supports preventive medicine, allowing healthcare systems to target screening programs and lifestyle interventions more effectively.

      5. By Supporting Clinical Decision-Making (Decision Support Systems):

      • Providing Insights and Recommendations: AI diagnostic systems often don’t just provide a diagnosis; they also highlight the evidence for that diagnosis, suggest differential diagnoses, and even recommend next steps or personalized treatment options.
        • How it’s required: AI acts as an intelligent assistant, offering real-time guidance and comprehensive insights to clinicians, helping them make more informed, evidence-based decisions about patient care.

      In essence, AI is required in healthcare diagnostics because it offers capabilities that are beyond human capacity in terms of speed, scale, and pattern recognition. It’s not about replacing humans but about augmenting human intelligence, reducing errors, improving efficiency, and ultimately, ensuring that patients receive faster, more accurate, and more accessible diagnoses, leading to better health outcomes.

      Case Study on AI in healthcare diagnostics—AI systems diagnosing diseases from medical data?

      Courtesy: AI & Health | IA & Santé

      Case Study: AI for Diabetic Retinopathy Screening in India (Aravind Eye Care System & Google)

      The Challenge: Diabetic retinopathy (DR) is a leading cause of blindness globally, and its prevalence is rapidly increasing in India due which is home to the second-highest number of people with diabetes worldwide. Early detection and timely treatment are crucial to prevent irreversible vision loss. However, India faces significant challenges:

      • Shortage of Ophthalmologists: Especially in rural and remote areas, there’s a severe shortage of retina specialists capable of accurately diagnosing DR from retinal images. This leads to missed diagnoses and delayed treatment.
      • High Volume of Patients: The sheer number of diabetic patients requiring regular screening is overwhelming for existing healthcare infrastructure.
      • Variability in Diagnosis: Human interpretation of retinal scans can be subjective, leading to inconsistencies.
      • Accessibility: Many patients, particularly in rural settings, cannot easily access specialized eye hospitals.

      The AI Solution: Recognizing this challenge, Google’s AI team collaborated with the Aravind Eye Care System (a renowned network of eye hospitals in Tamil Nadu, India, known for its high-volume, affordable eye care model) to develop and deploy an AI system for the automated detection of diabetic retinopathy.

      • Data & Training: Google’s deep learning algorithms were trained on a massive dataset of anonymized retinal images, meticulously graded by Aravind’s highly experienced ophthalmologists. This was a critical step, as access to high-quality, diverse, and well-labeled data is paramount for effective AI.
      • AI Model: The AI system is a deep learning model designed to analyze fundus photographs (images of the retina) and detect signs of DR, including microaneurysms, hemorrhages, and exudates, classifying the severity of the retinopathy.
      • Integration: The system is integrated into Aravind’s workflow, allowing technicians (who don’t necessarily need to be ophthalmologists) to capture retinal images, which the AI then analyzes within seconds.

      Impact and Success:

      • Improved Accessibility: The AI system can be deployed in rural vision centers, allowing patients to be screened without needing to travel to a major hospital to see a specialist.
      • Enhanced Efficiency: The AI quickly analyzes images, significantly reducing the workload on ophthalmologists by pre-screening clear cases and flagging suspicious ones for human review. This allows specialists to focus on complex cases.
      • Increased Accuracy: Studies have shown that the AI system’s performance in detecting referable DR (moderate or worse DR, or macular edema) is comparable to or even surpasses that of human specialists, with high sensitivity and specificity.
      • Scalability: The automated nature of the AI diagnosis makes large-scale screening programs feasible, reaching more diabetic patients who are at risk.
      • Cost-Effectiveness: By optimizing specialist time and enabling screening in lower-cost settings, the AI contributes to more affordable eye care.

      AI TRiSM in Action (Lessons Learned and Best Practices):

      This case study is a prime example of how AI TRiSM principles are essential:

      1. Fairness (Bias & Fairness Management):
        • Challenge Addressed: The collaboration with Aravind, which serves a diverse patient population across different socioeconomic strata, was crucial. The training data likely incorporated images from a wide range of patients, helping to mitigate potential biases that could arise if the AI was only trained on a narrow demographic.
        • TRiSM Implementation: Rigorous testing was performed to ensure the AI performed consistently and accurately across different patient demographics (e.g., age, gender, ethnicity) represented in the Aravind dataset. Ongoing monitoring would continue to check for fairness in real-world deployment.
      2. Transparency & Explainability (XAI):
        • Challenge Addressed: A “black box” AI that simply gives a diagnosis would not be trusted by clinicians.
        • TRiSM Implementation: While not fully transparent in the sense of showing all internal calculations, such systems typically provide:
          • Heatmaps/Highlights: Visual indications on the retinal image showing where the AI detected the abnormalities, allowing the ophthalmologist to visually confirm the AI’s “reasoning.”
          • Confidence Scores: The AI provides a probability score for its diagnosis, indicating its level of certainty.
          • Human-in-the-Loop: Crucially, the AI serves as a screening and decision-support tool. All AI-flagged cases still require final review and confirmation by a human ophthalmologist. This ensures accountability and builds trust.
      3. ModelOps (Model Operations & Lifecycle Management):
        • Challenge Addressed: AI models can degrade over time or perform differently on new patient populations or camera equipment.
        • TRiSM Implementation: Aravind and Google would implement:
          • Continuous Monitoring: Tracking the AI’s performance in real-time across various locations and devices to detect any drift in accuracy.
          • Feedback Loops: A system for ophthalmologists to provide feedback on AI-assisted diagnoses, which can be used to retrain and improve the model.
          • Regular Updates: As new data becomes available or as medical knowledge evolves, the AI model undergoes periodic retraining and validation.
      4. Privacy:
        • Challenge Addressed: Handling sensitive patient retinal images requires strict privacy protocols.
        • TRiSM Implementation: Google’s AI was trained on anonymized data. Strict data governance and security measures ensure patient privacy throughout data collection, storage, and processing.

      ConclusioThe Aravind-Google collaboration on AI for diabetic retinopathy screening serves as a powerful case study for AI in healthcare diagnostics in India. It demonstrates how AI can address critical healthcare gaps by increasing accessibility, improving efficiency, and enhancing diagnostic accuracy. More importantly, it exemplifies the inherent necessity of incorporating AI TRiSM principles—especially fairness, transparency, and human oversight—to build trustworthy AI systems that are clinically viable, ethically sound, and widely adopted for the benefit of patient care.

      White Paper on AI in Healthcare Diagnostics—AI Systems Diagnosing Diseases from Medical Data?

      White Paper: Revolutionizing Diagnostics – The Transformative Power of AI in Healthcare

      Abstract: The burgeoning volume and complexity of medical data present both immense opportunities and significant challenges for modern healthcare. This white paper explores the profound impact of Artificial Intelligence (AI) in healthcare diagnostics, detailing how AI systems are leveraging diverse medical data to enhance the accuracy, efficiency, and accessibility of disease diagnosis. We will delve into key AI methodologies, prominent applications across various medical domains, the substantial benefits realized, and critically, the imperative for robust AI Governance & Trust (AI TRiSM) to ensure these powerful technologies are developed and deployed fairly, transparently, and safely.

      1. Introduction: The Diagnostic Imperative in the Digital Age

      • The Evolving Healthcare Landscape: Discuss the increasing global burden of disease, aging populations, and the growing demand for healthcare services.
      • The Data Deluge: Highlight the exponential growth of medical data (EHRs, imaging, genomics, wearables) and the human challenge of processing it effectively.
      • Defining AI in Diagnostics: Introduce AI as a set of advanced computational methods capable of analyzing complex medical data to assist in identifying and predicting diseases.
      • The Promise of AI: Outline how AI aims to transform diagnostics from a reactive, labor-intensive process to a more proactive, precise, and personalized approach.

      2. Understanding AI in Diagnostics: Mechanisms and Methodologies

      • Core AI Techniques Employed:
        • Machine Learning (ML): Supervised, unsupervised, and reinforcement learning for pattern recognition and prediction.
        • Deep Learning (DL): Specifically Convolutional Neural Networks (CNNs) for image analysis, Recurrent Neural Networks (RNNs) for sequential data (like time-series patient vitals), and Transformers for contextual text analysis.
        • Natural Language Processing (NLP): For extracting structured information from unstructured clinical notes and reports.
        • Computer Vision: Enabling AI to “see” and interpret medical images.
      • Types of Medical Data Utilized:
        • Medical Imaging: X-rays, CT scans, MRIs, ultrasounds, mammograms, retinal scans, pathology slides, dermatological images.
        • Electronic Health Records (EHRs): Structured patient demographics, medical history, lab results, medication lists, vital signs.
        • Genomic and Multi-omics Data: DNA sequencing, gene expression, proteomics, metabolomics for personalized and precision medicine.
        • Physiological Signals: ECG, EEG, continuous glucose monitoring, heart rate data from wearables.
        • Clinical Notes & Reports: Unstructured text requiring advanced NLP.
      • How AI Diagnoses Diseases (Functional Capabilities):
        • Pattern Recognition & Anomaly Detection: Identifying subtle indicators of disease.
        • Classification: Categorizing data into disease states (e.g., malignant/benign).
        • Segmentation: Delineating specific structures or lesions within images.
        • Predictive Analytics: Forecasting disease risk, progression, or treatment response.
        • Decision Support: Providing probabilistic diagnoses, differential diagnoses, and treatment recommendations.

      3. Prominent Industrial Applications of AI in Diagnostics

      • Radiology:
        • Lung Cancer: Early detection of nodules in CT scans (e.g., Google Health’s AI for lung cancer screening).
        • Breast Cancer: Assisting radiologists in mammogram interpretation to reduce false positives/negatives.
        • Stroke: Rapidly identifying signs of stroke (ischemic or hemorrhagic) in brain scans for critical time-sensitive intervention.
        • Fracture Detection: Highlighting subtle fractures in X-rays, particularly in emergency settings.
      • Pathology:
        • Cancer Diagnosis: Analyzing digitized biopsy slides to identify cancerous cells, grade tumors, and predict treatment response (e.g., Paige.AI).
        • Disease Subtyping: Identifying specific subtypes of diseases based on cellular morphology.
      • Ophthalmology:
        • Diabetic Retinopathy: Automated screening from retinal images, a critical application in countries like India (e.g., Google-Aravind Eye Care System collaboration).
        • Glaucoma & Macular Degeneration: Early detection from retinal scans.
      • Cardiology:
        • Arrhythmia Detection: Analyzing ECG data for abnormal heart rhythms.
        • Heart Disease Risk Prediction: Using EHR data and imaging to predict cardiovascular events.
      • Dermatology:
        • Skin Cancer Screening: AI analysis of dermatoscopic images for suspicious lesions.
      • Rare Disease & Genetic Diagnosis:
        • Integrating complex genomic and phenotypic data to diagnose rare genetic disorders, accelerating diagnosis for patients who often endure long diagnostic odysseys.
      • Population Health & Screening Programs:
        • Tuberculosis (TB) Screening: AI analysis of chest X-rays for rapid and scalable TB detection in high-burden regions.
        • Sepsis Prediction: Real-time monitoring of vital signs and lab results to predict the onset of sepsis in critical care settings.

      4. The Transformative Benefits of AI in Healthcare Diagnostics

      • Enhanced Accuracy and Precision: Surpassing human capabilities in detecting subtle patterns, leading to earlier and more accurate diagnoses.
      • Increased Efficiency and Speed: Automating repetitive tasks, reducing analysis time, and accelerating diagnostic workflows, crucial for time-sensitive conditions.
      • Improved Accessibility: Bridging specialist gaps in underserved regions (e.g., rural India) by enabling local healthcare workers to perform AI-assisted screenings.
      • Reduced Human Error and Variability: Providing consistent, objective analysis, minimizing inter-observer discrepancies.
      • Personalized Medicine: Facilitating diagnoses and treatment recommendations tailored to an individual’s unique biological and genetic profile.
      • Cost Reduction: Optimizing resource utilization, reducing unnecessary tests, and preventing late-stage complications.
      • Proactive and Preventive Healthcare: Enabling early detection and risk prediction, shifting focus from reactive treatment to proactive intervention.

      5. The Indispensable Role of AI Governance & Trust (AI TRiSM)

      Given the high-stakes nature of healthcare diagnostics, AI TRiSM is not merely beneficial but absolutely essential for safe, ethical, and effective deployment.

      • Ensuring Fairness (Mitigating Bias):
        • Challenge: AI can inherit and amplify biases from unrepresentative training data, leading to misdiagnosis or delayed care for specific demographic groups (e.g., racial, gender, socioeconomic).
        • TRiSM Solution: Mandates diverse and representative data collection, rigorous bias detection tools, fairness-aware algorithmic design, and continuous monitoring for disparate impact across patient subgroups.
      • Promoting Transparency and Explainability (XAI):
        • Challenge: “Black box” AI decisions undermine clinician trust, hinder accountability, and impede patient understanding.
        • TRiSM Solution: Requires AI systems to provide clear explanations for their diagnoses (e.g., highlighting regions in images, citing contributing clinical factors), utilize confidence scores, and adhere to “human-in-the-loop” principles where the AI is a decision-support tool, not a final authority. Comprehensive documentation of model rationale is crucial.
      • Safeguarding Privacy:
        • Challenge: Handling sensitive patient health information demands stringent privacy protection.
        • TRiSM Solution: Enforces strict compliance with data privacy regulations (e.g., HIPAA, GDPR, India’s DPDPA), mandates data anonymization/pseudonymization, and encourages the use of privacy-preserving AI techniques (e.g., federated learning).
      • Fortifying AI Application Security:
        • Challenge: AI systems are vulnerable to unique cyber threats like adversarial attacks (manipulating input to trick AI) and data poisoning (corrupting training data), which could lead to dangerous misdiagnoses.
        • TRiSM Solution: Implements robust security measures throughout the AI lifecycle, from secure data pipelines and model integrity checks to adversarial robustness testing and incident response planning.
      • Robust ModelOps (Operational Management):
        • Challenge: AI model performance can degrade over time due to data drift or evolving disease patterns, leading to inaccuracies.
        • TRiSM Solution: Requires continuous monitoring of AI models in real-world clinical settings, automated detection of performance degradation, and systematic processes for model retraining, validation, and version control.
      • Regulatory Compliance and Accountability:
        • Challenge: Navigating complex and evolving medical device regulations and establishing clear lines of accountability for AI-driven outcomes.
        • TRiSM Solution: Supports adherence to national and international medical device regulations (e.g., FDA, EU AI Act), mandates ethical review boards, and establishes clear frameworks for liability and redress.

      6. Implementation Considerations for AI in Healthcare Diagnostics

      • Interdisciplinary Collaboration: Requires close partnership between AI developers, clinicians, ethicists, legal experts, and regulators.
      • High-Quality, Diverse Data: The ongoing need for ethically sourced, representative, and well-labeled datasets.
      • Scalable Infrastructure: Access to robust computing power (GPUs, cloud platforms) for training and deploying complex AI models.
      • Integration with Existing Workflows: Seamless integration of AI tools into clinical practice without disrupting current systems.
      • Training and Education: Comprehensive training for healthcare professionals on how to effectively and responsibly use AI tools.
      • Continuous Learning and Adaptation: AI systems must be designed to continuously learn and adapt as new medical knowledge emerges.

      7. Conclusion: The Future of Responsible AI-Powered Healthcare

      AI in healthcare diagnostics is poised to redefine the capabilities of modern medicine. From accelerating the detection of life-threatening diseases to democratizing access to expert diagnostic insights, its transformative potential is undeniable. However, realizing this potential fully and responsibly hinges on the unwavering commitment to AI Governance & Trust (AI TRiSM). By prioritizing fairness, transparency, privacy, and security throughout the entire AI lifecycle, healthcare organizations can build confidence in these powerful systems, navigate the ethical complexities, ensure regulatory compliance, and ultimately deliver a future where AI empowers clinicians to provide more accurate, equitable, and patient-centric care.

      Industrial Application of AI in Healthcare Diagnostics—AI Systems Diagnosing Diseases from Medical Data?

      Medical Imaging Analysis (Radiology & Pathology)

      This is arguably the most mature and widely adopted industrial application.

      • Application: AI algorithms analyze vast numbers of medical images (X-rays, CT scans, MRIs, mammograms, pathology slides) to detect abnormalities, classify lesions, and highlight areas of concern for human review.
      • Industrial Use Cases:
        • Early Cancer Detection: Companies like Qure.ai (India) are providing AI solutions for rapid chest X-ray analysis to detect lung abnormalities (including TB and lung cancer) and head CT scans for intracranial hemorrhages. Other firms specialize in mammography AI for breast cancer screening.
        • Diabetic Retinopathy Screening: AI systems are deployed in eye care clinics and mobile screening units to automatically analyze retinal images for signs of diabetic retinopathy, often without the immediate need for a specialist. The Google-Aravind Eye Care System collaboration in India is a prime example.
        • Digital Pathology: AI is used to analyze digitized biopsy slides, assisting pathologists in identifying cancerous cells, grading tumor aggressiveness, and even predicting treatment response. Companies like PathAI and Aiforia offer solutions that automate cell counting, tumor measurements, and biomarker detection.
        • Fracture Detection: AI tools can quickly identify subtle fractures in X-rays, particularly useful in emergency departments to reduce missed diagnoses.
        • Cardiac Imaging: AI analyzes cardiac MRI or CT scans to measure heart structures, identify blockages, and assess cardiac function, aiding in the diagnosis of heart disease.
      • Industrial Impact: Increased diagnostic throughput, reduced turnaround times, improved accuracy (especially for subtle findings), reduced workload for highly specialized professionals, and expanded access to advanced diagnostics in remote areas.

      2. Electronic Health Record (EHR) & Clinical Data Analysis

      • Application: AI, particularly Natural Language Processing (NLP) and machine learning, processes structured and unstructured data from EHRs (patient history, lab results, clinical notes) to identify patterns indicative of disease.
      • Industrial Use Cases:
        • Sepsis Prediction: AI continuously monitors patient vital signs, lab results, and other EHR data in ICUs to predict the onset of sepsis hours before clinical symptoms appear, allowing for early intervention.
        • Chronic Disease Management: Identifying patients at high risk for conditions like diabetes, heart failure, or kidney disease based on their comprehensive health data, enabling proactive management.
        • Rare Disease Diagnosis: AI can analyze vast amounts of disparate symptoms, medical history, and lab results to suggest potential rare disease diagnoses that might otherwise take years to identify.
        • Clinical Decision Support Systems: Integrating AI insights directly into physician workflows to provide real-time diagnostic suggestions and evidence-based recommendations.
      • Industrial Impact: Proactive disease management, reduced hospital readmissions, improved patient safety, and more personalized treatment pathways.

      3. Genomic and Multi-omics Diagnostics

      • Application: AI analyzes complex genomic sequences, gene expression data, and other “omics” data to identify genetic mutations, biomarkers, and pathways associated with diseases.
      • Industrial Use Cases:
        • Precision Oncology: Identifying specific genetic mutations in a patient’s tumor that can guide targeted therapies, predicting drug response and resistance (e.g., Tempus AI in cancer treatment).
        • Rare Genetic Disorder Diagnosis: AI helps pinpoint the genetic basis of rare diseases by sifting through vast genomic datasets and correlating genetic variations with clinical phenotypes.
        • Pharmacogenomics: Predicting how a patient will metabolize specific drugs based on their genetic makeup, allowing for personalized dosing and reduced adverse drug reactions.
      • Industrial Impact: Revolutionizing personalized medicine, accelerating drug discovery, and enabling more targeted and effective treatments.

      4. Point-of-Care and Remote Diagnostics

      • Application: AI is embedded in portable devices and telehealth platforms to enable diagnostics outside traditional hospital settings, often in underserved areas.
      • Industrial Use Cases:
        • Portable Ultrasound with AI: Handheld ultrasound devices with integrated AI can assist frontline clinicians in rapidly diagnosing conditions like gallstones or bladder issues.
        • Smartphone-based Diagnostics: Apps using AI to analyze images of skin lesions, ear infections, or even vocal biomarkers for neurological or mental health conditions.
        • Remote Patient Monitoring: AI analyzes data from wearables (e.g., smartwatches monitoring ECG) to detect arrhythmias or other cardiac abnormalities, triggering alerts for medical attention.
      • Industrial Impact: Dramatically improves accessibility to diagnostics in remote or resource-limited areas, enables continuous monitoring, and facilitates earlier interventions.

      5. Public Health and Population Screening Programs

      • Application: AI is used on a large scale for mass screening and public health surveillance.
      • Industrial Use Cases:
        • Mass TB Screening: AI-powered chest X-ray analysis systems are being deployed in India to quickly screen large populations for tuberculosis, especially in high-burden regions.
        • Predictive Epidemiology: AI models analyze vast health datasets to predict outbreaks of infectious diseases, enabling public health officials to deploy resources proactively.
      • Industrial Impact: Enhances public health surveillance, enables large-scale preventive measures, and optimizes resource allocation for public health initiatives.

      Key Challenges in Industrial Adoption (and why AI TRiSM is crucial):

      Despite the immense potential, the industrial application of AI in healthcare diagnostics faces several hurdles:

      • Regulatory Approval: AI diagnostic tools are often classified as medical devices and require stringent regulatory approval (e.g., FDA, EU AI Act, CDSCO in India), which demands robust validation and evidence of safety and efficacy.
      • Data Quality and Interoperability: AI thrives on high-quality, standardized data. The fragmentation and varying formats of medical data across different systems pose significant challenges.
      • Bias and Fairness: Ensuring AI models perform equitably across diverse patient populations is critical. Biased AI can exacerbate health disparities, leading to misdiagnoses for certain groups.
      • Transparency and Trust: Clinicians and patients need to understand how an AI arrives at a diagnosis. “Black box” models hinder adoption and accountability.
      • Integration with Existing Workflows: Seamless integration of AI tools into current clinical workflows and IT infrastructure is crucial for practical adoption.
      • Cost and ROI: High initial investment in AI infrastructure and talent can be a barrier for smaller healthcare providers.
      • Liability and Accountability: Determining who is responsible when an AI system makes an error.

      The industrial application of AI in healthcare diagnostics is not just about technology; it’s about transforming how healthcare is delivered. It requires a holistic approach that integrates advanced AI capabilities with robust governance, ethical considerations, and clinical validation to ensure these innovations truly benefit patients and healthcare systems at scale. Sources

      References

      [edit]

      1. ^ “Developing an aging clock using deep learning on retinal images”. ai.googleblog.com. 2023-04-11. Retrieved 2023-06-01.
      2. ^ Mullainathan S, Obermeyer Z (May 2022). “Solving medicine’s data bottleneck: Nightingale Open Science”. Nature Medicine. 28 (5): 897–899. doi:10.1038/s41591-022-01804-4. PMID 35534570. S2CID 248668494.
      3. ^ Jimma BL (2023-01-16). “Artificial intelligence in healthcare: A bibliometric analysis”. Telematics and Informatics Reports. 9: 100041. doi:10.1016/j.teler.2023.100041.
      4. ^ Lyakhova UA, Lyakhov PA (August 2024). “Systematic review of approaches to detection and classification of skin cancer using artificial intelligence: Development and prospects”. Computers in Biology and Medicine. 178: 108742. doi:10.1016/j.compbiomed.2024.108742. PMID 38875908.
      5. ^ Sankar H, Alagarsamy R, Lal B, Rana SS, Roychoudhury A, Agrawal A, et al. (2024). “Role of artificial intelligence in treatment planning and outcome prediction of jaw corrective surgeries using 3-D imaging: A systematic review”. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology. 139 (3): 299–310. doi:10.1016/j.oooo.2024.09.010. PMID 39701860.
      6. ^ Qiu Y, Cheng F (April 2024). “Artificial intelligence for drug discovery and development in Alzheimer’s disease”. Current Opinion in Structural Biology. 85: 102776. doi:10.1016/j.sbi.2024.102776. PMID 38335558.
      7. ^ Ghanem M, Ghaith AK, Bydon M (2024). “Artificial intelligence and personalized medicine: transforming patient care”. The New Era of Precision Medicine. Elsevier. pp. 131–142. doi:10.1016/b978-0-443-13963-5.00012-1. ISBN 978-0-443-13963-5. Retrieved 2024-10-10.
      8. ^ Snider V, Homsi K, Kusnoto B, Atsawasuwan P, Viana G, Allareddy V, et al. (May 2024). “Clinical evaluation of Artificial Intelligence Driven Remote Monitoring technology for assessment of patient oral hygiene during orthodontic treatment”. American Journal of Orthodontics and Dentofacial Orthopedics. 165 (5): 586–592. doi:10.1016/j.ajodo.2023.12.008. PMID 38363256.
      9. ^ Adams SJ, Henderson RD, Yi X, Babyn P (February 2021). “Artificial Intelligence Solutions for Analysis of X-ray Images”. Canadian Association of Radiologists Journal. 72 (1): 60–72. doi:10.1177/0846537120941671. PMID 32757950. S2CID 221036912.
      10. ^ Floridi L, Luetge C, Pagallo U, Schafer B, Valcke P, Vayena E, et al. (2019-09-01). “Key Ethical Challenges in the European Medical Information Framework”. Minds and Machines. 29 (3): 355–371. doi:10.1007/s11023-018-9467-4. hdl:2318/1728336. ISSN 1572-8641. S2CID 49668711.
      11. ^ Petersson L, Larsson I, Nygren JM, Nilsen P, Neher M, Reed JE, et al. (July 2022). “Challenges to implementing artificial intelligence in healthcare: a qualitative interview study with healthcare leaders in Sweden”. BMC Health Services Research. 22 (1): 850. doi:10.1186/s12913-022-08215-8. PMC 9250210. PMID 35778736.
      12. ^ Andrew Wong; Erkin Otles; John P. Donnelly; Andrew Krumm; Jeffrey McCullough; Olivia DeTroyer-Cooley; Justin Pestrue; Marie Phillips; Judy Konye; Carleen Penoza; Muhammad Ghous; Karandeep Singh (June 21, 2021). “External Validation of a Widely Implemented Proprietary Sepsis Prediction Model in Hospitalized Patients”. JAMA Internal Medicine. 181 (8): 1065–1070. doi:10.1001/jamainternmed.2021.2626. PMC 8218233. PMID 34152373.
      13. ^ Simonite T (June 21, 2021). “An Algorithm That Predicts Deadly Infections Is Often Flawed”. Wired Magazine.
      14. ^ Simonite T (October 24, 2019). “A health care algorithm offered less care to black patients”. Wired Magazine.
      15. ^ Ross C, Swetlitz I (September 5, 2017). “IBM pitched its Watson supercomputer as a revolution in cancer care. It’s nowhere close”. Stat.
      16. ^ Jump up to:a b Vo V, Chen G, Aquino YS, Carter SM, Do QN, Woode ME (December 2023). “Multi-stakeholder preferences for the use of artificial intelligence in healthcare: A systematic review and thematic analysis”. Social Science & Medicine. 338 (1): 116357. doi:10.1016/j.socscimed.2023.116357. PMID 37949020.
      17. ^ Scudellari M (March 29, 2021). “Machine Learning Faces a Reckoning in Health Research”. IEEE Spectrum.
      18. ^ Matthew B. A. McDermott, et al. (March 24, 2021). “Reproducibility in machine learning for health research: Still a ways to go”. Science Translational Medicine. 13 (586). doi:10.1126/scitranslmed.abb1655. PMID 33762434.
      19. ^ Varoquaux G, Cheplygina V (April 12, 2022). “Machine learning for medical imaging: methodological failures and recommendations for the future”. npj Digital Medicine. 5 (48): 48. doi:10.1038/s41746-022-00592-y. PMC 9005663. PMID 35413988.
      20. ^ Sohn E (January 9, 2023). “The reproducibility issues that haunt health-care AI”. Nature. 613 (7943): 402–403. Bibcode:2023Natur.613..402S. doi:10.1038/d41586-023-00023-2. PMID 36624237.
      21. ^ Jump up to:a b Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN, et al. (September 2023). “Revolutionizing healthcare: the role of artificial intelligence in clinical practice”. BMC Medical Education. 23 (1): 689. doi:10.1186/s12909-023-04698-z. PMC 10517477. PMID 37740191.
      22. ^ Liang H, Tsui BY, Ni H, Valentim CC, Baxter SL, Liu G, et al. (March 2019). “Evaluation and accurate diagnoses of pediatric diseases using artificial intelligence”. Nature Medicine. 25 (3): 433–438. doi:10.1038/s41591-018-0335-9. PMID 30742121. S2CID 59945159.
      23. ^ Li Q, Yang X, Xu J, Guo Y, He X, Hu H, et al. (August 2023). “Early prediction of Alzheimer’s disease and related dementias using real-world electronic health records”. Alzheimer’s & Dementia. 19 (8): 3506–3518. doi:10.1002/alz.12967. PMC 10976442. PMID 36815661. S2CID 257101613.
      24. ^ Jump up to:a b Ayers JW, Poliak A, Dredze M, Leas EC, Zhu Z, Kelley JB, et al. (2023). “Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum”. JAMA Internal Medicine. 183 (6): 589–596. doi:10.1001/jamainternmed.2023.1838. PMC 10148230. PMID 37115527.
      25. ^ See ‘Limitations’ section of Ayers et al. (2023)
      26. ^ “Expert reaction to study comparing physician and AI chatbot responses to patient questions”. Science Media Centre. April 28, 2023.
      27. ^ Shmerling RH (March 27, 2024). “Can AI answer medical questions better than your doctor?”. Harvard Health Publishing.
      28. ^ Ramezanpour A, Beam AL, Chen JH, Mashaghi A (November 2020). “Statistical Physics for Medical Diagnostics: Learning, Inference, and Optimization Algorithms”. Diagnostics. 10 (11): 972. doi:10.3390/diagnostics10110972. PMC 7699346. PMID 33228143.
      29. ^ Fayanju OM, Haut ER, Itani K (March 2025). “Practical Guide to Clinical Big Data Sources”. JAMA Surg. 160 (3): 344–346. doi:10.1001/jamasurg.2024.6006. PMID 39775674.
      30. ^ Jump up to:a b c d e Ferrante FE (June 2005). “Evolving telemedicine/ehealth technology”. Telemedicine Journal and e-Health. 11 (3): 370–383. doi:10.1089/tmj.2005.11.370. PMID 16035932.
      31. ^ Garza-Galicia, M., Sosa, M., Low, R., & Simini, F. (2017). Enseñanza de un Programa de Ortesis Mental Clínica: Experiencia con Estudiantes de Medicina en Uruguay. Memorias Del Congreso Nacional De Ingeniería Biomédica, 4(1), 91–94. Retrieved from: http://memorias.somib.org.mx/index.php/memorias/article/view/221 Archived 2021-08-13 at the Wayback Machine
      32. ^ Jump up to:a b c d Medrano IH, Guijarro JT, Belda C, Ureña A, Salcedo I, Anke LE, et al. (2018). “Savana: Re-using Electronic Health Records with Artificial Intelligence”. International Journal of Interactive Multimedia and Artificial Intelligence. 4 (7): 8–12. doi:10.9781/ijimai.2017.03.001. ISSN 1989-1660.
      33. ^ Jump up to:a b c Eren A, Subasi A, Coskun O (February 2008). “A decision support system for telemedicine through the mobile telecommunications platform”. Journal of Medical Systems. 32 (1): 31–35. doi:10.1007/s10916-007-9104-x. PMID 18333403. S2CID 11082133.
      34. ^ Bennett CC, Doub TW, Selove R (April 2012). “EHRs connect research and practice: Where predictive modeling, artificial intelligence, and clinical decision support intersect”. Health Policy and Technology. 1 (2): 105–114. arXiv:1204.4927. doi:10.1016/j.hlpt.2012.03.001. ISSN 2211-8837. S2CID 25022446.
      35. ^ Jump up to:a b Bokharaeian B, Diaz A, Chitsaz H (2016). “Enhancing Extraction of Drug-Drug Interaction from Literature Using Neutral Candidates, Negation, and Clause Dependency”. PLOS ONE. 11 (10): e0163480. Bibcode:2016PLoSO..1163480B. doi:10.1371/journal.pone.0163480. PMC 5047471. PMID 27695078.
      36. ^ Jump up to:a b c Cai R, Liu M, Hu Y, Melton BL, Matheny ME, Xu H, et al. (February 2017). “Identification of adverse drug-drug interactions through causal association rule discovery from spontaneous adverse event reports”. Artificial Intelligence in Medicine. 76: 7–15. doi:10.1016/j.artmed.2017.01.004. PMC 6438384. PMID 28363289.
      37. ^ Jump up to:a b Christopoulou F, Tran TT, Sahu SK, Miwa M, Ananiadou S (January 2020). “Adverse drug events and medication relation extraction in electronic health records with ensemble deep learning methods”. Journal of the American Medical Informatics Association. 27 (1): 39–46. doi:10.1093/jamia/ocz101. PMC 6913215. PMID 31390003.
      38. ^ Jump up to:a b Zhou D, Miao L, He Y (May 2018). “Position-aware deep multi-task learning for drug-drug interaction extraction” (PDF). Artificial Intelligence in Medicine. 87: 1–8. doi:10.1016/j.artmed.2018.03.001. PMID 29559249. S2CID 3951020.
      39. ^ García JS (2013-04-14). Optimización del tratamiento de enfermos pluripatológicos en atención primaria UCAMI HHUU Virgen del Rocio (Report). Sevilla. Spain – via ponencias de la II Reunión de Paciente Pluripatológico y Edad Avanzada Archived.
      40. ^ Herrero-Zazo M, Segura-Bedmar I, Martínez P, Declerck T (October 2013). “The DDI corpus: an annotated corpus with pharmacological substances and drug-drug interactions”. Journal of Biomedical Informatics. 46 (5): 914–920. doi:10.1016/j.jbi.2013.07.011. hdl:10016/20207. PMID 23906817.
      41. ^ Segura Bedmar I, Martínez P, Herrero Zazo M (June 2013). Semeval-2013 task 9: Extraction of drug-drug interactions from biomedical texts (ddiextraction 2013). Second Joint Conference on Lexical and Computational Semantics. Vol. 2. Association for Computational Linguistics. pp. 341–350.
      42. ^ Xu B, Shi X, Yin Y, Zhao Z, Zheng W, Lin H, et al. (July 2019). “Incorporating User Generated Content for Drug Drug Interaction Extraction Based on Full Attention Mechanism”. IEEE Transactions on NanoBioscience. 18 (3): 360–367. doi:10.1109/TNB.2019.2919188. PMID 31144641. S2CID 169038906.
      43. ^ Hamet P, Tremblay J (April 2017). “Artificial intelligence in medicine”. Metabolism. Insights Into the Future of Medicine: Technologies, Concepts, and Integration. 69S: S36 – S40. doi:10.1016/j.metabol.2017.01.011. PMID 28126242.
      44. ^ Jump up to:a b Pivovarov R, Elhadad N (September 2015). “Automated methods for the summarization of electronic health records”. Journal of the American Medical Informatics Association. 22 (5): 938–947. doi:10.1093/jamia/ocv032. PMC 4986665. PMID 25882031. S2CID 1452.
      45. ^ Yang M (October 2021). “Algorithms of Oppression: How Search Engines Reinforce RacismAlgorithms of Oppression: How Search Engines Reinforce Racism Safiya Umoja Noble NYU Press, 2018. 256 pp”. Science. 374 (6567): 35–44. doi:10.1177/2057047320950636. PMC 7441483.
      46. ^ “AI chatbots are here to help with your mental health, despite limited evidence they work”. The Economic Times. March 23, 2024. ISSN 0013-0389. Retrieved 2025-04-29.
      47. ^ “‘He checks in on me more than my friends and family’: can AI therapists do better than the real thing?”. The Guardian. 2024-03-02. ISSN 0261-3077. Retrieved 2025-04-29.
      48. ^ Ducharme J (2023-10-04). “Can AI Chatbots Ever Replace Human Therapists?”. TIME. Retrieved 2025-04-29.
      49. ^ Jump up to:a b c Pouke M, Häkkilä J (December 2013). “Elderly healthcare monitoring using an avatar-based 3D virtual environment”. International Journal of Environmental Research and Public Health. 10 (12): 7283–7298. doi:10.3390/ijerph10127283. PMC 3881167. PMID 24351747. S2CID 18535954.
      50. ^ Stokes F, Palmer A (October 2020). “Artificial Intelligence and Robotics in Nursing: Ethics of Caring as a Guide to Dividing Tasks Between AI and Humans”. Nursing Philosophy. 21 (4): e12306. doi:10.1111/nup.12306. PMID 32609420.
      51. ^ Jump up to:a b Wang H, Zu Q, Chen J, Yang Z, Ahmed MA (October 2021). “Application of Artificial Intelligence in Acute Coronary Syndrome: A Brief Literature Review”. Advances in Therapy. 38 (10): 5078–5086. doi:10.1007/s12325-021-01908-2. PMID 34528221. S2CID 237522871.
      52. ^ Infante T, Cavaliere C, Punzo B, Grimaldi V, Salvatore M, Napoli C (December 2021). “Radiogenomics and Artificial Intelligence Approaches Applied to Cardiac Computed Tomography Angiography and Cardiac Magnetic Resonance for Precision Medicine in Coronary Heart Disease: A Systematic Review”. Circulation: Cardiovascular Imaging. 14 (12): 1133–1146. doi:10.1161/CIRCIMAGING.121.013025. PMID 34915726. S2CID 245284764.
      53. ^ Sotirakos S, Fouda B, Mohamed Razif NA, Cribben N, Mulhall C, O’Byrne A, et al. (February 2022). “Harnessing artificial intelligence in cardiac rehabilitation, a systematic review”. Future Cardiology. 18 (2): 154–164. doi:10.2217/fca-2021-0010. PMID 33860679. S2CID 233258636.
      54. ^ Aghamohammadi M, Madan M, Hong JK, Watson I (2019). “Predicting Heart Attack Through Explainable Artificial Intelligence”. In Rodrigues JM, Cardoso PJ, Monteiro J, Lam R, Krzhizhanovskaya VV, Lees MH, Dongarra JJ, Sloot PM (eds.). Computational Science – ICCS 2019. Lecture Notes in Computer Science. Vol. 11537. Cham: Springer International Publishing. pp. 633–645. doi:10.1007/978-3-030-22741-8_45. ISBN 978-3-030-22741-8.
      55. ^ Chen W, Sun Q, Chen X, Xie G, Wu H, Xu C (May 2021). “Deep Learning Methods for Heart Sounds Classification: A Systematic Review”. Entropy. 23 (6): 667. Bibcode:2021Entrp..23..667C. doi:10.3390/e23060667. PMC 8229456. PMID 34073201.
      56. ^ Zhao Y, Wood EP, Mirin N, Cook SH, Chunara R (October 2021). “Social Determinants in Machine Learning Cardiovascular Disease Prediction Models: A Systematic Review”. American Journal of Preventive Medicine. 61 (4): 596–605. doi:10.1016/j.amepre.2021.04.016. PMID 34544559.
      57. ^ He B, Kwan AC, Cho JH, Yuan N, Pollick C, Shiota T, et al. (April 2023). “Blinded, randomized trial of sonographer versus AI cardiac function assessment”. Nature. 616 (7957): 520–524. Bibcode:2023Natur.616..520H. doi:10.1038/s41586-023-05947-3. PMC 10115627. PMID 37020027.
      58. ^ Mullainathan S, Obermeyer Z (2022). “”Diagnosing Physician Error: A Machine Learning Approach to Low-Value Health Care””. The Quarterly Journal of Economics. 137 (2): 679–727. doi:10.1093/qje/qjab046 – via Oxford Academic.
      59. ^ Bax M, Thorpe J, Romanov V (December 2023). “The future of personalized cardiovascular medicine demands 3D and 4D printing, stem cells, and artificial intelligence”. Frontiers in Sensors. 4. doi:10.3389/fsens.2023.1294721. ISSN 2673-5067.
      60. ^ Hibler BP, Qi Q, Rossi AM (March 2016). “Current state of imaging in dermatology”. Seminars in Cutaneous Medicine and Surgery. 35 (1): 2–8. doi:10.12788/j.sder.2016.001 (inactive 23 December 2024). PMID 26963110.
      61. ^ Chan S, Reddy V, Myers B, Thibodeaux Q, Brownstone N, Liao W (June 2020). “Machine Learning in Dermatology: Current Applications, Opportunities, and Limitations”. Dermatology and Therapy. 10 (3): 365–386. doi:10.1007/s13555-020-00372-0. PMC 7211783. PMID 32253623.
      62. ^ Han SS, Moon IJ, Lim W, Suh IS, Lee SY, Na JI, et al. (January 2020). “Keratinocytic Skin Cancer Detection on the Face Using Region-Based Convolutional Neural Network”. JAMA Dermatology. 156 (1): 29–37. doi:10.1001/jamadermatol.2019.3807. PMC 6902187. PMID 31799995.
      63. ^ Esteva A, Kuprel B, Novoa RA, Ko J, Swetter SM, Blau HM, et al. (February 2017). “Dermatologist-level classification of skin cancer with deep neural networks”. Nature. 542 (7639): 115–118. Bibcode:2017Natur.542..115E. doi:10.1038/nature21056. PMC 8382232. PMID 28117445. S2CID 3767412.
      64. ^ Noyan MA, Durdu M, Eskiocak AH (October 2020). “TzanckNet: a convolutional neural network to identify cells in the cytology of erosive-vesiculobullous diseases”. Scientific Reports. 10 (1): 18314. doi:10.1038/s41598-020-75546-z. PMC 7591506. PMID 33110197.
      65. ^ Adamson AS, Smith A (November 2018). “Machine Learning and Health Care Disparities in Dermatology”. JAMA Dermatology. 154 (11): 1247–1248. doi:10.1001/jamadermatol.2018.2348. PMID 30073260. S2CID 51907489.
      66. ^ “Computer learns to detect skin cancer more accurately than doctors”. The Guardian. 29 May 2018.
      67. ^ Jump up to:a b Haggenmüller S, Maron RC, Hekler A, Utikal JS, Barata C, Barnhill RL, et al. (October 2021). “Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts”. European Journal of Cancer. 156: 202–216. doi:10.1016/j.ejca.2021.06.049. PMID 34509059.
      68. ^ Han SS, Moon IJ, Kim SH, Na JI, Kim MS, Park GH, et al. (November 2020). “Assessment of deep neural networks for the diagnosis of benign and malignant skin neoplasms in comparison with dermatologists: A retrospective validation study”. PLOS Medicine. 17 (11): e1003381. doi:10.1371/journal.pmed.1003381. PMC 7688128. PMID 33237903.
      69. ^ Patcas R, Bernini DA, Volokitin A, Agustsson E, Rothe R, Timofte R (January 2019). “Applying artificial intelligence to assess the impact of orthognathic treatment on facial attractiveness and estimated age”. International Journal of Oral and Maxillofacial Surgery. 48 (1): 77–83. doi:10.1016/j.ijom.2018.07.010. PMID 30087062.
      70. ^ Patcas R, Timofte R, Volokitin A, Agustsson E, Eliades T, Eichenberger M, et al. (August 2019). “Facial attractiveness of cleft patients: a direct comparison between artificial-intelligence-based scoring and conventional rater groups”. European Journal of Orthodontics. 41 (4): 428–433. doi:10.1093/ejo/cjz007. hdl:20.500.11850/377316. PMID 30788496. S2CID 73507799.
      71. ^ Jump up to:a b Cao JS, Lu ZY, Chen MY, Zhang B, Juengpanich S, Hu JH, et al. (April 2021). “Artificial intelligence in gastroenterology and hepatology: Status and challenges”. World Journal of Gastroenterology. 27 (16): 1664–1690. doi:10.3748/wjg.v27.i16.1664. PMC 8072192. PMID 33967550.
      72. ^ “Artificial intelligence: 10 promising interventions for healthcare”. NIHR Evidence. National Institute for Health and Care Research. 28 July 2023. doi:10.3310/nihrevidence_59502.
      73. ^ Iacucci M, Parigi TL, Del Amor R, Meseguer P, Mandelli G, Bozzola A, et al. (June 2023). “Artificial Intelligence Enabled Histological Prediction of Remission or Activity and Clinical Outcomes in Ulcerative Colitis”. Gastroenterology. 164 (7): 1180–1188.e2. doi:10.1053/j.gastro.2023.02.031. hdl:2434/962515. PMID 36871598.
      74. ^ Kim HY, Cho GJ, Kwon HS (January 2023). “Applications of artificial intelligence in obstetrics”. Ultrasonography. 42 (1): 2–9. doi:10.14366/usg.22063. PMC 9816710. PMID 36588179.
      75. ^ Jump up to:a b Tran NK, Albahra S, May L, Waldman S, Crabtree S, Bainbridge S, et al. (December 2021). “Evolving Applications of Artificial Intelligence and Machine Learning in Infectious Diseases Testing”. Clinical Chemistry. 68 (1): 125–133. doi:10.1093/clinchem/hvab239. PMC 9383167. PMID 34969102.
      76. ^ Farhat F, Sohail SS, Alam MT, Ubaid S, Ashhad M, Madsen DØ (2023-11-08). “COVID-19 and beyond: leveraging artificial intelligence for enhanced outbreak control”. Frontiers in Artificial Intelligence. 6: 1266560. doi:10.3389/frai.2023.1266560. PMC 10663297. PMID 38028660.
      77. ^ Mann S, Berdahl CT, Baker L, Girosi F (October 2022). Pani D (ed.). “Artificial intelligence applications used in the clinical response to COVID-19: A scoping review”. PLOS Digital Health. 1 (10): e0000132. doi:10.1371/journal.pdig.0000132. PMC 9931281. PMID 36812557.
      78. ^ “AI could make health care fairer—by helping us believe what patients say”. MIT Technology Review. Retrieved 2023-06-03.
      79. ^ Pierson E, Cutler DM, Leskovec J, Mullainathan S, Obermeyer Z (January 2021). “An algorithmic approach to reducing unexplained pain disparities in underserved populations”. Nature Medicine. 27 (1): 136–140. doi:10.1038/s41591-020-01192-7. PMID 33442014. S2CID 256839494.
      80. ^ Khojaste-Sarakhsi M, Haghighi SS, Ghomi SM, Marchiori E (August 2022). “Deep learning for Alzheimer’s disease diagnosis: A survey”. Artificial Intelligence in Medicine. 130 (933–3657): 102332. doi:10.1016/j.artmed.2022.102332. PMID 35809971. S2CID 249633553.
      81. ^ “About ADNI”. 2017. Retrieved October 30, 2023.
      82. ^ Nguyen HD, Clément M, Mansencal B, Coupé P (21 September 2021). Deep Grading Based on Collective Artificial Intelligence for AD Diagnosis and Prognosis. Interpretability of Machine Intelligence in Medical Image Computing, and Topological Data Analysis and Its Applications for Medical Data. Springer, Cham. pp. 24–33. arXiv:2211.15192. doi:10.1007/978-3-030-87444-5_3.
      83. ^ Qu C, Zou Y, Ma Y, Chen Q, Luo J, Fan H, et al. (21 April 2022). “Diagnostic Performance of Generative Adversarial Network-Based Deep Learning Methods for Alzheimer’s Disease: A Systematic Review and Meta-Analysis”. Frontiers in Aging Neuroscience. 14: 841696. doi:10.3389/fnagi.2022.841696. PMC 9068970. PMID 35527734.
      84. ^ Fisher CK, Smith AM, Walsh JR (September 2019). “Machine learning for comprehensive forecasting of Alzheimer’s Disease progression”. Scientific Reports. 9 (1): 13622. arXiv:1807.03876. Bibcode:2019NatSR…913622F. doi:10.1038/s41598-019-49656-2. PMC 6754403. PMID 31541187.
      85. ^ Bhinder B, Gilvary C, Madhukar NS, Elemento O (April 2021). “Artificial Intelligence in Cancer Research and Precision Medicine”. Cancer Discovery. 11 (4): 900–915. doi:10.1158/2159-8290.CD-21-0090. PMC 8034385. PMID 33811123.
      86. ^ Majumder A, Sen D (October 2021). “Artificial intelligence in cancer diagnostics and therapy: current perspectives”. Indian Journal of Cancer. 58 (4): 481–492. doi:10.4103/ijc.IJC_399_20. PMID 34975094. S2CID 240522128.
      87. ^ Kobie N (1 January 2020). “DeepMind’s new AI can spot breast cancer just as well as your doctor”. Wired. Retrieved 1 January 2020.
      88. ^ McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. (January 2020). “International evaluation of an AI system for breast cancer screening”. Nature. 577 (7788): 89–94. Bibcode:2020Natur.577…89M. doi:10.1038/s41586-019-1799-6. hdl:10044/1/76203. PMID 31894144. S2CID 209523468.
      89. ^ McKinney SM, Sieniek M, Godbole V, Godwin J, Antropova N, Ashrafian H, et al. (January 2020). “International evaluation of an AI system for breast cancer screening”. Nature. 577 (7788): 89–94. Bibcode:2020Natur.577…89M. doi:10.1038/s41586-019-1799-6. hdl:10044/1/76203. PMID 31894144.
      90. ^ Heaven WD (November 12, 2020). “AI is wrestling with a replication crisis”. MIT Technology Review.
      91. ^ “Artificial intelligence identifies prostate cancer with near-perfect accuracy”. EurekAlert!. 27 July 2020. Retrieved 29 July 2020.
      92. ^ Pantanowitz L, Quiroga-Garza GM, Bien L, Heled R, Laifenfeld D, Linhart C, et al. (August 2020). “An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study”. The Lancet. Digital Health. 2 (8): e407 – e416. doi:10.1016/S2589-7500(20)30159-X. PMID 33328045.
      93. ^ Arthur A, Orton MR, Emsley R, Vit S, Kelly-Morland C, Strauss D, et al. (November 2023). “A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis”. The Lancet. Oncology. 24 (11): 1277–1286. doi:10.1016/S1470-2045(23)00462-X. PMC 10618402. PMID 37922931.
      94. ^ “Scientists excited by AI tool that grades severity of rare cancer”. BBC News. 2023-11-01. Retrieved 2023-11-12.
      95. ^ Ravindran S (April 2019). “How artificial intelligence is helping to prevent blindness”. Nature. doi:10.1038/d41586-019-01111-y. PMID 32269369. S2CID 146005413.
      96. ^ Office of the Commissioner (2020-03-24). “FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems”. FDA. Archived from the original on May 1, 2019. Retrieved 2023-02-11.
      97. ^ Han JH (August 2022). “Artificial Intelligence in Eye Disease: Recent Developments, Applications, and Surveys”. Diagnostics. 12 (8): 1927. doi:10.3390/diagnostics12081927. PMC 9406878. PMID 36010277.
      98. ^ Lourenço BC, Guimarães-Teixeira C, Flores BC, Miranda-Gonçalves V, Guimarães R, Cantante M, et al. (February 2022). “Ki67 and LSD1 Expression in Testicular Germ Cell Tumors Is Not Associated with Patient Outcome: Investigation Using a Digital Pathology Algorithm”. Life. 12 (2): 264. Bibcode:2022Life…12..264L. doi:10.3390/life12020264. PMC 8875543. PMID 35207551.
        – Figure 2 – available via license: Creative Commons Attribution 4.0 International
      99. ^ Jump up to:a b c d e Försch S, Klauschen F, Hufnagl P, Roth W (March 2021). “Artificial Intelligence in Pathology”. Deutsches Ärzteblatt International. 118 (12): 194–204. doi:10.3238/arztebl.m2021.0011. PMC 8278129. PMID 34024323.
      100. ^ Steiner DF, MacDonald R, Liu Y, Truszkowski P, Hipp JD, Gammage C, et al. (December 2018). “Impact of Deep Learning Assistance on the Histopathologic Review of Lymph Nodes for Metastatic Breast Cancer”. The American Journal of Surgical Pathology. 42 (12): 1636–1646. doi:10.1097/PAS.0000000000001151. PMC 6257102. PMID 30312179.
      101. ^ Ho J, Ahlers SM, Stratman C, Aridor O, Pantanowitz L, Fine JL, et al. (2014). “Can digital pathology result in cost savings? A financial projection for digital pathology implementation at a large integrated health care organization”. Journal of Pathology Informatics. 5 (1): 33. doi:10.4103/2153-3539.139714. PMC 4168664. PMID 25250191.
      102. ^ Jurmeister P, Bockmayr M, Seegerer P, Bockmayr T, Treue D, Montavon G, et al. (September 2019). “Machine learning analysis of DNA methylation profiles distinguishes primary lung squamous cell carcinomas from head and neck metastases”. Science Translational Medicine. 11 (509): eaaw8513. doi:10.1126/scitranslmed.aaw8513. PMID 31511427. S2CID 202564269.
      103. ^ Mistry P (September 2019). “Artificial intelligence in primary care”. The British Journal of General Practice. 69 (686): 422–423. doi:10.3399/bjgp19X705137. PMC 6715470. PMID 31467001.
      104. ^ Blease C, Kaptchuk TJ, Bernstein MH, Mandl KD, Halamka JD, DesRoches CM (March 2019). “Artificial Intelligence and the Future of Primary Care: Exploratory Qualitative Study of UK General Practitioners’ Views”. Journal of Medical Internet Research. 21 (3): e12802. doi:10.2196/12802. PMC 6446158. PMID 30892270. S2CID 59175658.
      105. ^ Liyanage H, Liaw ST, Jonnagaddala J, Schreiber R, Kuziemsky C, Terry AL, et al. (August 2019). “Artificial Intelligence in Primary Health Care: Perceptions, Issues, and Challenges”. Yearbook of Medical Informatics. 28 (1): 41–46. doi:10.1055/s-0039-1677901. PMC 6697547. PMID 31022751.
      106. ^ Herter WE, Khuc J, Cinà G, Knottnerus BJ, Numans ME, Wiewel MA, et al. (May 2022). “Impact of a Machine Learning-Based Decision Support System for Urinary Tract Infections: Prospective Observational Study in 36 Primary Care Practices”. JMIR Medical Informatics. 10 (5): e27795. doi:10.2196/27795. PMC 9118012. PMID 35507396. S2CID 246819392.
      107. ^ Savage N (January 2022). “Robots rise to meet the challenge of caring for old people”. Nature. 601 (7893): S8 – S10. Bibcode:2022Natur.601S…8S. doi:10.1038/d41586-022-00072-z. PMID 35046591. S2CID 246064292.
      108. ^ Graham S, Depp C, Lee EE, Nebeker C, Tu X, Kim HC, et al. (November 2019). “Artificial Intelligence for Mental Health and Mental Illnesses: an Overview”. Current Psychiatry Reports. 21 (11): 116. doi:10.1007/s11920-019-1094-0. PMC 7274446. PMID 31701320.
      109. ^ Chekroud AM, Bondar J, Delgadillo J, Doherty G, Wasil A, Fokkema M, et al. (June 2021). “The promise of machine learning in predicting treatment outcomes in psychiatry”. World Psychiatry. 20 (2): 154–170. doi:10.1002/wps.20882. PMC 8129866. PMID 34002503.
      110. ^ Fulmer R, Joerin A, Gentile B, Lakerink L, Rauws M (December 2018). “Using Psychological Artificial Intelligence (Tess) to Relieve Symptoms of Depression and Anxiety: Randomized Controlled Trial”. JMIR Mental Health. 5 (4): e64. doi:10.2196/mental.9782. PMC 6315222. PMID 30545815.
      111. ^ Coppersmith G, Leary R, Crutchley P, Fine A (January 2018). “Natural Language Processing of Social Media as Screening for Suicide Risk”. Biomedical Informatics Insights. 10: 1178222618792860. doi:10.1177/1178222618792860. PMC 6111391. PMID 30158822.
      112. ^ Brunn M, Diefenbacher A, Courtet P, Genieys W (August 2020). “The Future is Knocking: How Artificial Intelligence Will Fundamentally Change Psychiatry”. Academic Psychiatry. 44 (4): 461–466. doi:10.1007/s40596-020-01243-8. PMID 32424706. S2CID 218682746.
      113. ^ Rutledge RB, Chekroud AM, Huys QJ (April 2019). “Machine learning and big data in psychiatry: toward clinical applications”. Current Opinion in Neurobiology. Machine Learning, Big Data, and Neuroscience. 55: 152–159. doi:10.1016/j.conb.2019.02.006. PMID 30999271. S2CID 115202826.
      114. ^ Crimmins T (2023-05-30). “‘This robot causes harm’: National Eating Disorders Association’s new chatbot advises people with disordering eating to lose weight”. The Daily Dot. Retrieved 2023-06-02.
      115. ^ Knight T (May 31, 2023). “Eating disorder helpline fires AI for harmful advice after sacking humans”.
      116. ^ Aratani L (2023-05-31). “US eating disorder helpline takes down AI chatbot over harmful advice”. The Guardian. ISSN 0261-3077. Retrieved 2023-06-01.
      117. ^ Jump up to:a b c d Pisarchik AN, Maksimenko VA, Hramov AE (October 2019). “From Novel Technology to Novel Applications: Comment on “An Integrated Brain-Machine Interface Platform With Thousands of Channels” by Elon Musk and Neuralink”. Journal of Medical Internet Research. 21 (10): e16356. doi:10.2196/16356. PMC 6914250. PMID 31674923. S2CID 207818415.
      118. ^ Jump up to:a b Hosny A, Parmar C, Quackenbush J, Schwartz LH, Aerts HJ (August 2018). “Artificial intelligence in radiology”. Nature Reviews. Cancer. 18 (8): 500–510. doi:10.1038/s41568-018-0016-5. PMC 6268174. PMID 29777175.
      119. ^ Liu X, Faes L, Kale AU, Wagner SK, Fu DJ, Bruynseels A, et al. (October 2019). “A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis”. The Lancet. Digital Health. 1 (6): e271 – e297. doi:10.1016/S2589-7500(19)30123-2. PMID 33323251. S2CID 204037561.
      120. ^ Georgescu MI, Ionescu RT, Miron AI, Savencu O, Ristea NC, Verga N, et al. (2023). Multimodal Multi-Head Convolutional Attention With Various Kernel Sizes for Medical Image Super-Resolution (Report). IEEE/CVF Winter Conference on Applications of Computer Vision. pp. 2195–2205.
      121. ^ Richardson ML, Garwood ER, Lee Y, Li MD, Lo HS, Nagaraju A, et al. (September 2021). “Noninterpretive Uses of Artificial Intelligence in Radiology”. Academic Radiology. 28 (9): 1225–1235. doi:10.1016/j.acra.2020.01.012. PMID 32059956.
      122. ^ Seifert R, Weber M, Kocakavuk E, Rischpler C, Kersting D (March 2021). “Artificial Intelligence and Machine Learning in Nuclear Medicine: Future Perspectives”. Seminars in Nuclear Medicine. 51 (2): 170–177. doi:10.1053/j.semnuclmed.2020.08.003. PMID 33509373. S2CID 224863373.
      123. ^ Pacilè S, Lopez J, Chone P, Bertinotti T, Grouin JM, Fillard P (November 2020). “Improving Breast Cancer Detection Accuracy of Mammography with the Concurrent Use of an Artificial Intelligence Tool”. Radiology: Artificial Intelligence. 2 (6): e190208. doi:10.1148/ryai.2020190208. PMC 8082372. PMID 33937844.
      124. ^ Erh-Chun, Shan L, Chan P (2023-10-01). “How Artificial Intelligence is Transforming Agriculture”. Review of Business Research. 23 (1): 59–70. doi:10.18374/rbr-23-1.6. ISSN 1546-2609.
      125. ^ Li L (2023). “Emerging technologies for carbon reduction in building industry: Evidence from patent inventions”. AHFE International. Human Interaction & Emerging Technologies (IHIET 2023): Artificial Intelligence & Future Applications. 111. doi:10.54941/ahfe1004073. ISBN 978-1-958651-87-2.
      126. ^ Choi D, Mirbod O, Ilodibe U, Kinsey S (2023-11-09). “Understanding Artificial Intelligence: What It Is and How It Is Used in Agriculture”. EDIS. 2023 (6). doi:10.32473/edis-ae589-2023. ISSN 2576-0009.
      127. ^ Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP (2023-07-10). “Artificial Intelligence in Pharmaceutical Technology and Drug Delivery Design”. Pharmaceutics. 15 (7): 1916. doi:10.3390/pharmaceutics15071916. ISSN 1999-4923. PMC 10385763. PMID 37514102.
      128. ^ Khan O, Parvez M, Kumari P, Parvez S, Ahmad S (2023). “The future of pharmacy: How AI is revolutionizing the industry”. Intelligent Pharmacy. 1 (1): 32–40. doi:10.1016/j.ipha.2023.04.008.
      129. ^ Chaudhary S, Muthudoss P, Madheswaran T, Paudel A, Gaikwad V (2023), “Artificial intelligence (AI) in drug product designing, development, and manufacturing”, A Handbook of Artificial Intelligence in Drug Delivery, Elsevier, pp. 395–442, doi:10.1016/B978-0-323-89925-3.00015-0, ISBN 978-0-323-89925-3, retrieved 2025-04-26
      130. ^ “AI for Pharmacist #6 Identifying AI Education Needs in Pharmaceutical Sciences”. www.linkedin.com. Retrieved 2025-04-26.
      131. ^ Jump up to:a b c d Quan XI, Sanderson J (December 2018). “Understanding the Artificial Intelligence Business Ecosystem”. IEEE Engineering Management Review. 46 (4): 22–25. doi:10.1109/EMR.2018.2882430. ISSN 0360-8581. S2CID 59525052.
      132. ^ Jump up to:a b c d e f g h i j Webster P (May 2025). “US AI regulatory rollback and health”. The Lancet. 405 (10490): 1654–1656. doi:10.1016/S0140-6736(25)00980-8.
      133. ^ “HEALS”. Institute for Data Exploration and Applications (IDEA). nd. Retrieved 2025-05-27.
      134. ^ McCarthy J (2016-05-31). “Intel Capital invests $10 million in medical artificial intelligence”. Healthcare IT News. Retrieved 2024-01-28.
      135. ^ Tung L (September 20, 2016). “Microsoft’s next big AI project? Helping ‘solve’ cancer”. ZDNET. Retrieved 2024-01-28.
      136. ^ Carpenter J (2021-04-07). “Meet the Chatbots That Might Manage Your Money One Day”. Wall Street Journal. ISSN 0099-9660. Retrieved 2022-06-30.
      137. ^ Jump up to:a b Abou-Zahra S, Brewer J, Cooper M (2018-04-23). “Artificial Intelligence (AI) for Web Accessibility”. Proceedings of the 15th International Web for All Conference. W4A ’18. Lyon, France: Association for Computing Machinery. pp. 1–4. doi:10.1145/3192714.3192834. ISBN 978-1-4503-5651-0. S2CID 49863409.
      138. ^ Jump up to:a b Guo J, Li B (2018-08-01). “The Application of Medical Artificial Intelligence Technology in Rural Areas of Developing Countries”. Health Equity. 2 (1): 174–181. doi:10.1089/heq.2018.0037. PMC 6110188. PMID 30283865.
      139. ^ Collins GS, Moons KG, Dhiman P, Riley RD, Beam AL, Van Calster B, et al. (April 2024). “TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods”. BMJ. 385: e078378. doi:10.1136/bmj-2023-078378. PMC 11019967. PMID 38626948.
      140. ^ Vasey B, Nagendran M, Campbell B, Clifton DA, Collins GS, Denaxas S, et al. (May 2022). “Reporting guideline for the early stage clinical evaluation of decision support systems driven by artificial intelligence: DECIDE-AI”. BMJ. 377: e070904. doi:10.1136/bmj-2022-070904. PMC 9116198. PMID 35584845.
      141. ^ Liu X, Cruz Rivera S, Moher D, Calvert MJ, Denniston AK (September 2020). “Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: the CONSORT-AI extension”. Nature Medicine. 26 (9): 1364–1374. doi:10.1038/s41591-020-1034-x. PMC 7598943. PMID 32908283.
      142. ^ Office of the Commissioner (2022-11-30). “About FDA”. FDA. Retrieved 2023-04-08.
      143. ^ “Civil Rights for Providers of Health Care and Human Services”. hhs.gov. Office for Civil Rights. 2015-09-05. Retrieved 2022-12-17.
      144. ^ Jump up to:a b “Artificial Intelligence and Machine Learning in Software as a Medical Device”. FDA. 2023-10-20.
      145. ^ “HHS Artificial Intelligence (AI) Strategy”. www.hhs.gov. 2021-12-22. Retrieved 2023-11-25.
      146. ^ “Cambridge Core – Journals & Books Online | Cambridge University Press”. Cambridge Core. Retrieved 2022-12-17.
      147. ^ Jump up to:a b Forcier MB, Gallois H, Mullan S, Joly Y (October 2019). “Integrating artificial intelligence into health care through data access: can the GDPR act as a beacon for policymakers?”. Journal of Law and the Biosciences. 6 (1): 317–335. doi:10.1093/jlb/lsz013. PMC 6813940. PMID 31666972.
      148. ^ “Sharing and Utilizing Health Data for AI Applications”. hhs.gov.
      149. ^ Van Kolfschooten H (2022-02-01). “EU regulation of artificial intelligence: Challenges for patients’ rights” (PDF). Common Market Law Review. 59 (1): 81–112. doi:10.54648/COLA2022005. ISSN 0165-0750. S2CID 248591427.
      150. ^ Lacassie E, Marquet P, Martin-Dupont S, Gaulier JM, Lachâtre G (September 2000). “A non-fatal case of intoxication with foxglove, documented by means of liquid chromatography-electrospray-mass spectrometry”. Journal of Forensic Sciences. 45 (5): 1154–1158. doi:10.1520/JFS14845J. PMID 11005196.
      151. ^ Mudgal KS, Das N (2020-11-01). “The ethical adoption of artificial intelligence in radiology”. BJR Open. 2 (1): 20190020. doi:10.1259/bjro.20190020. PMC 7605209. PMID 33178959.
      152. ^ Rainie L, Funk C, Anderson M, Tyson A (2022-03-17). “1. How Americans think about artificial intelligence”. Pew Research Center. Retrieved 2024-06-11.
      153. ^ Jump up to:a b Davenport T, Kalakota R (June 2019). “The potential for artificial intelligence in healthcare”. Future Healthcare Journal. 6 (2): 94–98. doi:10.7861/futurehosp.6-2-94. PMC 6616181. PMID 31363513.
      154. ^ Jump up to:a b Baric-Parker J, Anderson EE (November 2020). “Patient Data-Sharing for AI: Ethical Challenges, Catholic Solutions”. The Linacre Quarterly. 87 (4): 471–481. doi:10.1177/0024363920922690. PMC 7551527. PMID 33100395.
      155. ^ Mann S, Berdahl CT, Baker L, Girosi F (October 2022). “Artificial intelligence applications used in the clinical response to COVID-19: A scoping review”. PLOS Digital Health. 1 (10): e0000132. doi:10.2196/42936. PMC 11041459. PMID 38875587. S2CID 256681439.
      156. ^ Backman I. “Eliminating Racial Bias in Health Care AI: Expert Panel Offers Guidelines”. medicine.yale.edu. Retrieved 2025-02-28.
      157. ^ Jump up to:a b Nordling L (September 2019). “A fairer way forward for AI in health care”. Nature. 573 (7775): S103 – S105. Bibcode:2019Natur.573S.103N. doi:10.1038/d41586-019-02872-2. PMID 31554993. S2CID 202749329.
      158. ^ Reddy S, Allan S, Coghlan S, Cooper P (March 2020). “A governance model for the application of AI in health care”. Journal of the American Medical Informatics Association. 27 (3): 491–497. doi:10.1093/jamia/ocz192. PMC 7647243. PMID 31682262.
      159. ^ Pumplun L, Fecho M, Wahl N, Peters F, Buxmann P (October 2021). “Adoption of Machine Learning Systems for Medical Diagnostics in Clinics: Qualitative Interview Study”. Journal of Medical Internet Research. 23 (10): e29301. doi:10.2196/29301. PMC 8556641. PMID 34652275. S2CID 238990562.
      160. ^ Evans M, Mathews AW (2019-10-24). “Researchers Find Racial Bias in Hospital Algorithm”. Wall Street Journal. ISSN 0099-9660. Retrieved 2023-06-03.
      161. ^ Lindsay RK, Buchanan BG, Feigenbaum EA, Lederberg J (1993). “DENDRAL: a case study of the first expert system for scientific hypothesis formation”. Artificial Intelligence. 61 (2): 209–261. doi:10.1016/0004-3702(93)90068-m. hdl:2027.42/30758.
      162. ^ Lea AS (2023). Digitizing Diagnosis: Medicine, Minds, and Machines in Twentieth-Century America. Johns Hopkins University Press. pp. 1–256. ISBN 978-1-4214-4681-3.
      163. ^ Jump up to:a b Clancey WJ, Shortliffe EH (1984). Readings in medical artificial intelligence: the first decade. Addison-Wesley Longman Publishing Co., Inc.
      164. ^ Bruce G, Buchanan BG, Shortliffe ED (1984). Rule-based expert systems: the MYCIN experiments of the Stanford Heuristic Programming Project.
      165. ^ Duda RO, Shortliffe EH (April 1983). “Expert Systems Research”. Science. 220 (4594): 261–268. Bibcode:1983Sci…220..261D. doi:10.1126/science.6340198. PMID 6340198.
      166. ^ Miller RA (1994). “Medical diagnostic decision support systems–past, present, and future: a threaded bibliography and brief commentary”. Journal of the American Medical Informatics Association. 1 (1): 8–27. doi:10.1136/jamia.1994.95236141. PMC 116181. PMID 7719792.
      167. ^ Adlassnig KP (July 1980). “A fuzzy logical model of computer-assisted medical diagnosis”. Methods of Information in Medicine. 19 (3): 141–148. doi:10.1055/s-0038-1636674. PMID 6997678.
      168. ^ Reggia JA, Peng Y (September 1987). “Modeling diagnostic reasoning: a summary of parsimonious covering theory”. Computer Methods and Programs in Biomedicine. 25 (2): 125–134. doi:10.1016/0169-2607(87)90048-4. PMC 2244953. PMID 3315427.
      169. ^ Baxt WG (December 1991). “Use of an artificial neural network for the diagnosis of myocardial infarction”. Annals of Internal Medicine. 115 (11): 843–848. doi:10.7326/0003-4819-115-11-843. PMID 1952470.
      170. ^ Maclin PS, Dempsey J, Brooks J, Rand J (February 1991). “Using neural networks to diagnose cancer”. Journal of Medical Systems. 15 (1): 11–19. doi:10.1007/bf00993877. PMID 1748845. S2CID 10189561.
      171. ^ Koomey J, Berard S, Sanchez M, Wong H (March 2010). “Implications of historical trends in the electrical efficiency of computing”. IEEE Annals of the Hist
      International Institute Of Technology

      Contact Detail

      • B-401, Om Kaveri CHS Ltd, Nagindas Pada, Next to Shivsena Office, Nalasopara (East),
        Dist.- Palghar Maharastra 401209
      • admin@iitinstitute.org
      • +91-8668266780

      Sitemap

      Academics

      About Us

      Disclaimer

      Policies

      Resources

      Facilities

      Services

      Research and Industry

      Students

      Divisions

      iitinstitute.org

      Follow Us

      Facebook Twitter Youtube Linkedin
      The Swachh Bharat Mission logo featuring Mahatma Gandhi’s iconic round spectacles. The words "Swachh" and "Bharat" are written inside the lenses in Devanagari script, with a small Indian tricolor bridge between them. The tagline "Ek Kadam Swachhta Ki Ore" is written below.
      A black and white logo featuring the silhouette of a lion made entirely of interlocking gears and mechanical cogs, with the words "MAKE IN INDIA" written in bold white capital letters across its body.
      The "Digital India" logo featuring a blue and orange geometric design resembling an 'i' with a globe at the top, accompanied by the text "Digital India" and the tagline "Power To Empower" in both English and Hindi.
      G20 India 2023
      The "Azadi Ka Amrit Mahotsav" logo featuring a stylized number 75 in gold, the Indian tricolor flag waving to the right, and the event name written in Hindi script below.

      2025. Copyright iitinstitute.org

      Scroll to Top